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25  Abstract
26  The aetiology of multiple sclerosis (MS) is as yet poorly understood. Multiple 
27 mechanisms in different disease stages are responsible for immunopathology in MS. HLA 
28 Class II DR2b (DRB1*1501 β, DRA1*0101 α) is the strongest genetic risk factor for MS. 
29 Remnants of ancient retroviruses in the human genome, termed human endogenous 
30 retroviruses (HERV), and Epstein-Barr virus (EBV) infection are also associated with MS. In 
31 silico analyses of human endogenous retroviral envelope (HERV env) proteins and three 
32 myelin proteins that are principal targets of an autoimmune response in MS showed 
33 sequence similarities between potential TH epitopes within pairs of viral and myelin peptides 
34 predicted to bind HLA DR2b. This led to the proposal that such molecular mimicry may 
35 potentially trigger MS. HLA DR2b binding characteristics of previously identified peptides 
36 from the three myelin proteins and HERV env proteins as well as additional in silico 
37 predicted peptides from other encephalitogenic brain proteins and EBV proteins were 
38 studied to further investigate molecular mimicry. Peptides containing potential TH epitopes 
39 from the myelin oligodendrocyte glycoprotein and HERV env previously predicted to bind 
40 HLA DR2b as well as other pertinent potential HLA DR2b-restricted TH  epitopes were 
41 confirmed to bind HLA DR2b molecules.  Molecular modelling of HLA DR2b in complex with 
42 high affinity peptides derived from MOG and HERV env proteins showed that their binding 
43 could occur in a similar manner to a HLA DR2b-binding peptide containing a known TH 
44 epitope.  A structurally related pair of peptides predicted to bind HLA DR2b from the EBV 
45 protein EBNA1 and β synuclein, a brain protein implicated in MS, were also shown to 
46 similarly bind HLA DR2b. The findings justify investigating CD4+ T cell responses to the 
47 identified peptides. 
48  
49 Key Words: autoimmunity; Epstein-Barr virus; HLA DR2b-peptide complex; human 
50 endogenous retroviruses; molecular mimicry; multiple sclerosis.
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51  1. Introduction
52 Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central 
53 nervous system (CNS) that involves progressive damage to the myelin sheath and axons 
54 leading to neurodegeneration [1 - 3]. Studies on MS patients and experimental allergic 
55 (autoimmune) encephalomyelitis (EAE) in rodents have implicated several CNS proteins, 
56 prominently myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and 
57 proteolipid protein (PLP), as targets of an autoimmune response in MS [1 - 3]. However, the 
58 aetiology of MS is not well understood. Cells of the innate immune system, CD4+ helper T 
59 cells (TH), CD8+ cytotoxic T cells and antibodies are involved in the immunopathology of MS, 
60 while TH among all types of antigen-specific cells, are considered to have the critical role in 
61 initiating an autoimmune process [1 - 3]. Environmental factors, e.g. vitamin D deficiency [4], 
62 and infection with Epstein Barr virus (EBV) [1-2, 5-8], have been implicated in predisposition 
63 to MS. Genome-wide association studies identified the HLA Class II allele DRB1*1501 β 
64 chain variant, which pairs with the relatively invariant DRA1*0101 α chain to form the HLA 
65 DR2b heterodimer in antigen-presenting cells (APCs), as the strongest genetic risk factor for 
66 MS [9]. The production of virions and expression of envelope protein (env) of a member of 
67 the genome-encoded human endogenous retrovirus W-family (HERV-W), termed the MS- 
68 associated retrovirus or MSRV [10], has also been implicated in MS [11 - 15]. However, the 
69 molecular mechanisms linking TH cells to genetic elements in the aetiology of MS are not 
70 established.  A molecular mimicry hypothesis has been advanced that epitopes in MSRV 
71 and possibly other HERV family env proteins that cross-react with epitopes in myelin 
72 proteins, and presented by HLA DR2b on APCs to TH cells in an inflammatory milieu, 
73 provide the requisite link [16]. 
74 Regions of amino acid sequence homology have been demonstrated by BLAST 
75 analysis between MBP, MOG and PLP on one hand and MSRV env on the other [16, 17]. In 
76 addition, regions with amino acid sequence homologies are found between the myelin 
77 proteins and syncytin-1 (SYN1) [16], another HERV-W family-derived env protein that has 
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78 evolved to perform an essential role in forming the syncytiotrophoblast of the placenta [18]. 
79 SYN1 is 87% identical in amino acid sequence to MSRV env [16] and also more distantly 
80 related to syncytin-2 (SYN2), another essential fusogenic placental protein derived from a 
81 different HERV family termed HERV-FRD [19]. SYN2 also possesses regions of amino acid 
82 sequence homology with the three myelin proteins [16]. SYN1 has an additional fusogenic 
83 role in the development of myotubes from myoblasts [20] and possibly osteoclasts [21].  
84 In silico analyses utilizing the Immune Epitope Data Base (IEDB) [22] to predict 
85 HLA DR2b-binding 15mer peptides showed amino acid sequence similarities between 
86 potential nonamer TH epitopes within the 15mers from the HERV env proteins and all three 
87 myelin proteins that are predicted to bind to HLA DR2b with high (IC50<50nM) or 
88 intermediate affinity (50nM<IC50<500nM) [16]. Sequence similarities between a potential 
89 nonamer epitope in MOG and those in MSRV env, SYN1 and SYN2 were particularly 
90 prominent [16]. Interestingly, some predicted higher affinity HLA DR2b-binding peptides with 
91 sequence similarities lie within longer regions of sequence homology between myelin 
92 proteins and HERV env proteins whilst others do not [16]. Since SYN1 and SYN2 have 
93 evolved to perform essential physiological functions in humans, it is possible that TH cells 
94 that react with them may be deleted in the thymus and/or regulatory T cells (Tregs) that 
95 dampen an immune response are selected against them. This may not apply to MSRV env 
96 which is not expected to be normally expressed during development. However MSRV env is 
97 expressed within innate immune cells in an inflammatory situation, e.g. during EBV infection 
98 [23], and is a potent stimulant of Toll-like receptor 4 present on macrophages and microglia 
99 [12, 24], leading to neuronal damage [12] and impaired functional maturation of myelin-
100 producing oligodendrocytes [24]. While existing data are compatible with an initiating role for 
101 molecular mimicry between the MSRV env and myelin proteins in MS, it is unclear whether 
102 this extends to the related SYN1 and SYN2 molecules. Once MS has been initiated in the 
103 proposed manner [16], further damage could arise from TH cells recognising other myelin 
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104 epitopes presented by different HLA Class II molecules as a result of epitope spreading [16, 
105 25].   
106 This study experimentally investigated HLA DR2b binding of 15mer peptides 
107 derived from MBP, MOG, PLP and HERV env proteins earlier identified in silico as 
108 potentially able to bind to HLA DR2b [16]. It also examined HLA DR2b-binding of peptides 
109 from additional CNS proteins reported to be encephalitogenic [1] that had sequence 
110 similarities to corresponding peptides present in HERV env proteins or EBV proteins that 
111 elicit prominent human CD4+ T cell responses [2].  Pertinent peptides that bound HLA DR2b 
112 were also examined by molecular modelling of peptide–HLA DR2b complexes.
113
114 2. Materials and Methods
115 2.1 Selection of CNS proteins for investigation
116 The three myelin proteins previously used for in silico analysis of peptides 
117 capable of binding to HLA DR2b [16] and six other CNS proteins reported to be 
118 encephalitogenic [1, 26] selected for the present study are listed in Table 1.
119 Table 1. CNS proteins selected for investigation
Protein Abbreviation NCBI sequence ID
Myelin basic protein MBP P02686.3
Myelin oligodendrocyte glycoprotein MOG Q16653.2
Phospholipid protein PLP P60201.2
α, β Crystallin ABP ACP18852
Myelin-associated oligodendrocyte basic protein MOPB NP_001265251.1
Oligodendrocyte-specific protein OSP AAC25187
2’3’ Cyclic nucleotide 3’ phosphodiesterase CNPase P09543
Myelin-associated glycoprotein MAG AAH53347.1
6
β-Synuclein βSYN Q16143
120 Legend to Table 3. NCBI – National Centre for Biological Information, Bethesda, MD.
121
122 2.2 Selection of HERV and EBV proteins for investigation
123 The three HERV env proteins used previously for predicting HLA DR2b-restricted 
124 peptides through the IEDB in silico procedure [16] and six EBV proteins reported to elicit 
125 strong human CD4+ T cell responses [2] were initially selected for the present study (Table 
126 2). 
127 Table 2. Virus-derived proteins selected for investigation
Virus protein Abbreviation NCBI sequence ID
HERV-W Syncytin-1 SYN1 Q9UQF0
HERV-FRD Syncytin-2 SYN2 NP_997465
HERV-W Multiple sclerosis-associated retrovirus 
envelope protein
MSRV env AAK18189.1
Epstein-Barr nuclear antigen 1 EBNA1 YP_401677.1
Epstein-Barr nuclear antigen 2 EBNA2 ALV83014.1
Epstein-Barr nuclear antigen 3C EBNA3C CEQ33769.1
Epstein-Barr virus transactivator BZLF1 BZLF1 CAD53423
Epstein-Barr virus glycoprotein BZLF2 BZLF2 CEQ33770.1
Epstein-Barr virus envelope glycoprotein H BXLF2 ATE89094.1
128 Legend to Table 3. NCBI – National Centre for Biological Information, Bethesda, MD.
129
130 2.3 Sequence homologies between CNS and virus-derived proteins
131 The additional CNS coding sequences obtained from the US National Center for 
132 Biotechnology Information (NCBI) data base were compared by pairwise Basic Local 
133 Alignment Search Tool (BLASTp) analysis online using default parameters 
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134 (https://www.ncbi.nlm.nih.gov/blast) against HERV env proteins, as previously described for 
135 MBP, MOG, PLP and the three HERV env proteins SYN1, SYN2 and MSRV env [16]. Each 
136 of the CNS proteins shown in Table 1 were also individually tested in BLASTp searches for 
137 regions of homology against all non-redundant protein sequences of EBV (human herpes 
138 virus 4 strain B95-8) with NCBI taxonomy ID 10377. 
139
140 2.4 Prediction of peptides potentially binding to HLA DR2b molecules
141 Prediction of potential peptides binding to HLA DR2b molecules was performed 
142 as previously described [16] using the IEDB analysis resource (www.iedb.org) [22, 27, 28]. 
143 The default peptide length of 15 amino acids was used in the analysis but the results also 
144 show the core nonamers that are expected to bind to the HLA DR2b molecule and constitute 
145 the major portion of the T cell epitope [22, 27, 28]. The Stabilised Matrix Method (SMM) was 
146 used to rank the peptides according to their predicted binding affinities or IC50 which 
147 indicates the nM concentration of peptide expected to bind and achieve 50% saturation of 
148 the HLA DR2b molecules [22, 27, 28]. Sequence similarities between core nonamer 
149 sequences in 15mer peptides that were predicted to bind HLA DR2b with high or 
150 intermediate affinity (IC50<500nM) were manually identified within pairs of proteins.  
151
152 2.5 Determination of the binding affinity and stability of HLA DR2b-peptide complexes
153 Peptides (15mers) were synthesized by FMOC solid-phase chemistry and quality 
154 checked with matrix assisted laser desorption ionization-time of flight mass spectrometry 
155 (MALDI-TOF MS) by ProImmune (Oxford, UK). Binding characteristics of the peptides to 
156 HLA DR2b were then determined by ProImmune using the cell-free REVEAL® MHC class II 
157 binding assay [29]. The REVEAL® assay measured the ability of a peptide to stabilize the 
158 MHC-peptide complex based on detection of the native conformation of the MHC-peptide 
159 complex with a specific monoclonal antibody [29]. After an initial incubation with peptide for 
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160 determining the proportion of MHC molecules binding the peptide to measure affinity, an 
161 additional measurement was taken after a further 24h incubation at 370C to measure 
162 stability. The stability provides information on whether peptide can be bound long enough to 
163 serve as a T cell epitope. Affinity and stability indices were measured as a percentage of the 
164 signal generated by the test peptide in comparison to a proprietary ProImmune positive 
165 control peptide. A well characterised 15mer MBP peptide with the sequence 
166 ENPVVHFFKNIVTPR (hereafter referred to as MBP_3) that is presented by HLA DR2b and 
167 activates CD4+ T cells [30] was chosen as the internal comparative standard in the assays. 
168 Details of the two sets of 40 peptides from CNS and viral proteins that were 
169 tested in the HLA DR2b binding assays are provided in Supplementary Table S1. The first 
170 set of 40 contained sequence-related peptides derived from MBP (including the control 
171 peptide MBP_3), MOG, PLP, SYN1 and MSRV env previously identified in silico using the 
172 IEDB algorithm as being potentially important for molecular mimicry [16]. Staggered arrays 
173 of 15mers were used to identify the best binding peptide in the REVEAL® assay. The first set 
174 also contained a 15mer derived from EBV DNA polymerase shown to cross-react at the 
175 CD4+ T cell level with the control peptide MBP_3 on presentation by HLA DR2b [30]. A 
176 different HLA DR2b-restricted MOG epitope shown previously to stimulate CD4+ T cells to 
177 produce IFNγ [31] was also included in the first set of peptides. Others in the first set were 
178 four MSRV env 15mer peptides with the nonamer sequence TSVLVGPLV that exhibited 
179 weaker sequence homology to MOG nonamer IVLPVLGPLV [16].
180 The second set of 40 peptides (Supplementary Table S1) were chosen to 
181 replicate and further examine the binding characteristics of the more promising HLA DR2b-
182 binding peptides identified from first set. They were independently synthesised and tested in 
183 REVEAL® binding assays. The second set additionally tested sequence-related pairs of 
184 HLA DR2b-binding peptides identified through IEDB in silico analysis in EBNA1 and HERV 
185 env proteins on one hand and different CNS proteins on the other. They included peptide 
186 pairs from EBNA1 and βSYN as well as EBNA1 and OSP that had also been predicted to 
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187 bind HLA DR2b using a different algorithm in an unrelated study [32], and peptide pairs from 
188 MSRV env and OSP. The second set also included a different MBP peptide reported to be 
189 recognised by TH cells in the context of HLA DR2b [33].
190
191 2.6 Modelling of 15mer peptides binding to HLA DR2b
192 Molecular modelling of the HLA DR2b-peptide complexes were performed using 
193 the in silico docking program HADDOCK (high ambiguity driven protein-protein docking) [34]. 
194 Coordinates for the HLA DR2b complex were retrieved from the Protein Data Bank entry 
195 1YMM [35]. Initial coordinates for the DR2b-restricted peptide moieties were extracted from 
196 the crystal structure of the T cell receptor(TCR)/HLA DR2b/MBP_3-peptide complex (entry 
197 1YMM), and then used to build models of peptides with the molecular builder tool in COOT 
198 [36]. Each HLA DR2b-restricted peptide was subsequently subjected to a short 
199 regularisation protocol to ensure that the geometry of the peptide residues conformed to 
200 known bond lengths and angles. 
201 The docking procedure was driven using only ambiguous intermolecular 
202 restraints, which were defined based on previously determined HLA DR2b-peptide 
203 complexes [35, 37, 38]. These structures revealed that the MBP_3 peptide is bound in the 
204 HLA DR2b peptide-binding groove with peptide side chains P1, P4, P6 and P9 occupying 
205 pockets within the groove. Hence residues that line the P1, P4, P6 and P9 pockets of HLA 
206 DR2b were selected as active residues (comprised of E11α, F24α, F32α, W43α, F54α, 
207 N62α, D66α, R76α, R13β, F26β, D28β, Q70β, A71β, Y78β, D57β and W61β). For the 
208 peptide only the anchor residue side chains at P1, P4, P6 and P9 were defined as active 
209 residues. Passively involved residues were selected automatically. The 200 structures 
210 obtained after water refinement were analysed and ranked according to their HADDOCK 
211 score, a weighted sum of electrostatic, van der Waals, and restraint energy terms [34]. The 
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212 lowest energy structure solutions were visualised and analysed using Pymol (The PyMOL 
213 Molecular Graphics System, Version 1.8 Schrödinger, LLC).  
214
215 3. Results
216 3.1 Sequence homologies between CNS and EBV or HERV env proteins
217 Regions of sequence homologies between the three HERV env proteins and the 
218 three myelin proteins MBP, MOG and PLP observed in BLASTp analysis have been 
219 previously described [16]. BLASTp analysis of each of the selected CNS proteins against all 
220 the non-redundant protein sequences coded in whole EBV genome revealed only a single 
221 region of weak homology between α, β crystallin (ABP) and a 53 residue segment of the 
222 EBV protein EBNA4 (NCBI Protein ID P03203.3) with an E value of 0.95 (Supplementary 
223 Table S2). Pairwise BLASTp analysis of each of the six newly selected CNS proteins against 
224 the three HERV env proteins demonstrated regions of homology with E≤0.5 only between 
225 the pairs ABP and SYN2, ABP and MSRV env, and myelin-associated glycoprotein (MAG) 
226 and MSRV env (Supplementary Table S3). 
227                                               
228 3.2 Structurally related peptides in CNS and EBV or HERV env proteins predicted to 
229 bind to HLA DR2b molecules 
230 IEDB analysis of MBP, MOG, PLP on one hand and the three HERV env 
231 proteins on the other, that identified 15mer peptides containing  sequence-related nonamers 
232 predicted to bind to HLA DR2b were previously described [16]. Similar IEDB analysis was 
233 performed on the additional CNS proteins ABP, MAG, OSP and βSYN (Supplementary 
234 Table S4,) and on the EBV proteins EBNA1 and EBNA4 (Supplementary Table S5). ABP, 
235 MAG and EBNA4 were selected because of relevant regions of sequence homology 
236 identified in section 3.1, while EBNA1, OSP and βSYN were chosen because of the 
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237 prediction of pertinent HLA DR2b binding peptides in an independent study [32]. 
238 Examination of the IEDB results from the protein pairs ABP/SYN2, ABP/MSRV env and 
239 MAG/MSRV env, using data in Table S4 and published data in reference 16 did not identify 
240 15mer peptides of potentially high or intermediate affinity of binding to HLA DR2b that also 
241 contained sequence-related nonamers. Nonamers of similar sequences were however found 
242 in predicted HLA DR2b-binding 15mers from the pair OSP/MSRV env.  Analysis of IEDB 
243 results in Supplementary Tables S4 & S5 showed sequence-related pairs of potential HLA 
244 DR2b-binding peptides of high or intermediate affinity also in EBNA1/OSP and 
245 EBNA1/βSYN. The pairs of peptides containing structurally related, predicted HLA DR2b-
246 binding nonamers, with their sequences shown in Supplementary Table S6, were 
247 subsequently investigated in HLA DR2b binding assays. 
248  
249 3.3 Experimental binding to HLA DR2b of CNS and viral peptides predicted in silico to 
250 bind HLA DR2b
251 The results of REVEAL binding assays on the selected peptides (Supplementary 
252 Table S6) showed that the pairs of peptides from MOG and the corresponding three HERV 
253 env proteins containing sequence-related nonamers previously predicted to engage HLA 
254 DR2b [16], and implicated in molecular mimicry, are able to bind HLA DR2b with comparable 
255 affinities and stabilities to the control MBP_3 peptide. A peptide from βSYN containing a 
256 predicted HLA DR2b-binding nonamer of sequence GVLYVGSKT and two similarly 
257 predicted peptides from EBNA1 with the related nonamer sequence VFVYGGSKT also 
258 bound to HLA DR2b with binding characteristics comparable to MBP_3 (Supplementary 
259 Table S6). 
260 The results also show that some OSP peptides with similar nonamer sequences 
261 to EBNA1 and MSRV env peptides and with predicted in silico intermediate binding affinity 
262 are able to bind well to HLA DR2b. However, the corresponding 15mer viral peptides did not 
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263 bind strongly to HLA DR2b. For example, the OSP 15mer STTLRALAPRLMRRV which 
264 bound strongly had five identities in its predicted nonamer HLA DR2b-binding sequence 
265 (LRALAPRLM)  to the corresponding nonamer (LRALLARSH) in two 15mer EBNA1 peptides 
266 that however only showed weak binding to HLA DR2b (Supplementary Table S6). 
267 Peptides from the closely related signal sequences of SYN1 and MSRV that 
268 contained sequence-related nonamers to those in internal peptides of MBP (including the 
269 control peptide MBP_3) and PLP identified previously [16] did not bind strongly to HLA DR2b 
270 in the assays. Only one PLP peptide TASFFFLYGALLLAE that contained the nonamer 
271 sequence FFFLYGALL that was predicted to bind strongly to HLA DR2b [16] was confirmed 
272 to bind strongly to HLA DR2b. Four MSRV env peptides tested containing the nonamer 
273 sequence TSVLVGPLV with weaker sequence homology to the MOG nonamer 
274 IVLPVLGPLV did not bind to HLA DR2b. 
275 Peptides from EBV DNA polymerase and a different MOG region that had been 
276 shown to be presented on HLA DR2b and stimulate CD4+ T cells [30, 31] revealed significant 
277 binding affinity to HLA DR2b in the assay. A MBP peptide (GTLSKIFKLGGRDSR) containing 
278 a putative HLA DR2b-resticted T cell epitope [33] but with a weak predicted IC50 of 940nM 
279 based on IEDB analysis, only demonstrated marginal binding to HLA DR2b.
280 An exact correlation between the in silico predicted affinity (IC50) and the 
281 experimentally determined affinity by the REVEAL® binding assay for HLA DR2b was not 
282 observed. For example, some PLP peptides with high predicted affinity (IC50<1nM) showed 
283 poor experimental binding, while four SYN2 peptides with predicted intermediate affinities 
284 (IC50 of 130 to 149nM) had experimental binding comparable to MBP_3 (Supplementary 
285 Table S6). 
286 Data on the best binding 15mer peptides with nonamers relevant for molecular 
287 mimicry, grouped together and compared with the binding of the control MBP peptide are 
288 listed in Table 3. 
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290 Table 3. Binding characteristics and Haddock scores of the best pairs of HLA DR2b-










1. MOG & 
HERV env
MOG_4 ITLFVIVPVLGPLVA 151 110 -123.7±2.5
MSRV env _5 MPWTLPFLGPLAAII 69 33 -158.1±2.1
SYN1_2 MPWILPFLGPLAAII 144 124 -152.5±4.4
SYN2_5 KWFSWVLPLTGPLVS 348 181 -137.8±5.3
2. βSYN & 
EBNA1
β synuclein EKTKEGVLYVGSKTR 91 95 -128.7±3.0
EBNA1_2 VAGVFVYGGSKTSLY 118 43 -131.5±5.1
3. Control MBP_3 ENPVVHFFKNIVTPR 100 100 -163.7±1.6
293 Legend to Table 3. Results show the experimentally determined relative affinity and stability of 
294 binding of peptides expressed as a percentage of that observed with the control MBP_3 peptide 
295 assigned values of 100. The nonamers sequence predicted to bind in the peptide-binding groove in 
296 HLA DR2b are shown in bold letters and underlined. The docking scores for the HADDOCK-derived 
297 lowest energy HLA DR2b-peptide complex models are shown.
298
299 3.4 Molecular models of sequence-related peptides binding to HLA DR2b
300 We employed in silico molecular docking strategies to understand the molecular 
301 mechanisms governing binding of the structurally related pairs of peptides by HLA DR2b and 
302 their potential recognition by TCR. To evaluate the feasibility of using such approaches we 
303 first modelled the binding of the control MBP_3 peptide ENPVVHFFKNIVTPR to HLA DR2b 
304 using HADDOCK and then compared with the available crystallographic structure (PDB 
305 entry 1YMM) [35, 37, 38].  The HLA DR2b-MBP_3 complex model corresponding to the 
306 lowest intermolecular energy (with a HADDOCK score of -163.7) shows substantial similarity 
307 with the published structure in terms of epitope conformation and docking mode (Figure 1A). 
308 Superposition of the MBP_3 peptides derived from the published and model complex 
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309 structures show that the main chain conformation is highly conserved (Figure 1A).  In 
310 addition, similar to the published structure, the modelled MBP-3 peptide side chains at P1, 
311 P4, P6 and P9 serve as anchors slotting into the HLA DR2b antigen binding cleft (Figure 
312 1B&C). Finally, in both the published and modelled complexes, the peptide was held in the 
313 HLA DR2b antigen-binding cleft by a conserved network of hydrogen bonding and non-polar 
314 interactions (Figure 1B&C). These observations justified the use of the HADDOCK docking 
315 approach to generate models of HLA DR2b bound to peptides that are relevant to MS.   
316 To address the molecular mimicry hypothesis we generated models of HLA 
317 DR2b in complex with peptides of the highest affinity derived from MOG and the HERV env 
318 proteins MRSV env, SYN1 and SYN2 that are shown in Table 3. Superposition of the MOG, 
319 MSRV env, SYN1 and SYN2 peptides show that they all adopt a very similar back-bone 
320 conformation (Figure 2A).  Similarly to the control MBP_3 peptide, the P1, P4, P6 and P9 
321 peptide side chain positions serve as anchors inserting into the HLA DR2b antigen binding 
322 cleft (Figure 2B-D). The HLA DR2b-peptide interactions were remarkably conserved 
323 between the different complexes including the control HLA DR2b-MBP_3 complex.  In 
324 addition, positions P-1, P2, P5, and P8 are predicted to be surface exposed in the 
325 HADDOCK derived HLA DR2b-peptide complex models, and therefore potentially involved in 
326 binding to the TCR. The chemical characteristics of these prominent solvent exposed 
327 residues were either identical or structurally related in the relevant pairs of peptides. Taken 
328 together, these findings support the molecular mimicry hypothesis between MOG and HERV 
329 env proteins in MS.
330 HADDOCK derived models of HLA DR2b in complex with the βSYN and EBNA1 
331 peptides shown in Table 3 were also generated (Figure 3). These peptides adopted similar 
332 main chain conformations (Figure 3A) and mediated a conserved network of polar and non-
333 polar interactions with side chains of HLA DR2b (Figure 3 B&C). As with comparisons 
334 between MOG and HERV env proteins, the most prominent surface exposed residues (at P-
15
335 1, P2, P5, and P8) and hence potential TCR contacts were mainly conserved or semi-
336 conservatively substituted between the βSYN and EBNA1 peptide pair. 
337 It is noteworthy that surface-exposed residues that can contact TCRs were 
338 however significantly different between the two sets of unrelated peptide pairs βSYN/EBNA1 
339 and HERV env/MOG, and between each of these and MBP_3 (Table 3 and Figures 1-3).
340 The HADDOCK docking scores of the best binding 15mer peptides possessing 
341 the relevant sequence-related nonamer pairs are listed in Table 3. The HADDOCK scores 
342 do not correlate with experimentally measured REVEAL® binding affinities or stability indices 
343 for the peptides but the high negative values point towards energetically favourable binding 
344 to HLA DR2b molecules.  
345
346 4. Discussion
347 More recent findings are pertinent to the originally proposed HERV-related 
348 molecular mimicry hypothesis [16]. EBV, which primarily infects B cells, has been further 
349 implicated as a necessary but not sufficient cause of MS, partly because of its increased and 
350 dysregulated expression in peripheral blood and brain [39 -43]. In addition, antibody titres to 
351 EBNA1 have lately been re-confirmed to be higher in MS patients compared to controls [44]. 
352 EBNA1 has recently been reported to promote alternative splicing of cellular genes [45]. 
353 Since EBNA1 is widely expressed in EBV infected cells [46], it is intriguing to speculate that 
354 its splicing activity has a role in the trans splicing that has been postulated to produce 
355 functional MSRV env molecules [17]. This adds to the many different mechanisms proposed 
356 to explain why EBV infections are a predisposition for MS [1-2, 5-8].
357 HERVs and their putative role in autoimmunity have been lately reviewed [47-49] 
358 and cross-reactive B cell epitopes in MOG and HERV-W env have been documented [50]. 
359 The presence of antibodies to HERV-W env proteins have recently been reported to 
360 differentiate MS from related neurological diseases [51, 52]. Recent data also show that 
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361 MSRV env is present in microglia associated with myelinated axons in MS lesions, MSRV 
362 env induces inflammatory myelin and neuron damaging activity in microglia in vitro and that 
363 antibodies to MSRV env are neuroprotective in MS patients [12]. These observations are 
364 pertinent to further examining a role for potential molecular mimicry between MSRV env and 
365 MOG in triggering MS.
366 Evidence that human GDP-L-fucose synthase peptides are recognised by CD4+ 
367 T cells in the context of HLA DRB3 *0202 in MS patients, and that gut bacterial GDP-L-
368 fucose synthase may be cross-reactive has led to a different proposal for molecular mimicry 
369 in MS [53]. RAS guanyl releasing protein 2 in peripheral memory B cells driving the 
370 proliferation of brain-infiltrating CD4+ TH1 in a HLA DR2b-restricted manner that then 
371 recognise epitopes from the same protein expressed in CNS cells has been proposed as 
372 another autoimmune mechanism explaining the association between MS and HLA DR2b 
373 [54]. 
374 The molecular mimicry hypothesis proposed previously [16] was supported by 
375 the in silico identification of sequence-related pairs of 15mer peptides predicted to bind HLA 
376 DR2b in myelin-associated MBP, MOG and PLP proteins on one hand and HERV env 
377 proteins on the other. Sequence homologies were particularly prominent between the 
378 predicted MOG and HERV env peptides [16] and the present study confirmed that these 
379 predicted peptides are indeed able to bind to HLA DR2b with characteristics comparable 
380 with the well-known TH epitope in MBP_3. Such binding was not demonstrable for the HERV 
381 env peptides identified previously that were related in sequence to peptides from MBP and 
382 PLP [16]. However the corresponding MBP peptides and one PLP peptide have been shown 
383 to bind HLA DR2b.  
384 The peptides containing sequence-related nonamers with potential TH epitopes 
385 in MSRV env, SYN1, SYN2 and MOG have the capacity to bind to HLA DR2b molecules 
386 with similar binding topology to the well characterised MBP_3 peptide containing a TH 
387 epitope. The molecular modelling suggests that potential surface exposed residues that 
17
388 contact TCR are relatively conserved between the MOG and HERV env peptides which is 
389 consistent with the proposed molecular mimicry hypothesis. The MOG peptide is located in 
390 the predicted C terminal transmembrane domain of MOG. The corresponding HLA DR2b-
391 binding nonamers from MSRV env, SYN1 and SYN2 are also sited in predicted 
392 transmembrane domains.  A longer peptide from the transmembrane region of MOG, that 
393 contained the MOG peptide identified in the present work, has independently been shown to 
394 stimulate CD4+ T cells from MS patients to proliferate and secrete IFNγ in a HLA DRB-
395 restricted manner [55]. It is possible that SYN1 and SYN2 may normally elicit tolerance as 
396 they may be recognised as self-proteins. MSRV env on the other hand may function as a 
397 foreign protein that can generate autoimmunity through molecular mimicry in an 
398 inflammatory milieu, possibly driven by EBV infection, within the CNS or outside it as 
399 previously discussed [16]. Studies on CD4+ T cell responses to the peptides identified in this 
400 study will help clarify the potential roles of MOG and the three HERV env proteins in the 
401 immunopathogenesis of MS. It is relevant in this context that TCR recognition of MBP_3 
402 bound to HLA DR2b has been shown to involve skewed binding, not typical of TCR binding 
403 foreign peptide-Class II MHC complexes, which can result in potentially weaker interactions 
404 that may permit autoimmune T cells to escape deletion in the thymus [37]. 
405 This study also identified a pair of sequence-related nonamers derived from 
406 βSYN and EBNA1 that showed binding affinity and stability comparable to MBP_3 in the 
407 REVEAL® assay for HLA DR2b. This pair of peptides had been independently predicted to 
408 bind HLA DR2b [32].   Modelling of the βSYN and EBNA1 peptides with HLA DR2b revealed 
409 binding to the peptide binding cleft similar to MBP_3 and relative conservation of the surface 
410 exposed, potential TCR contact residues in the two peptides. This suggests the molecular 
411 mimicry is possible between the βSYN and EBNA1 peptides. It is relevant in this context that 
412 βSYN-reactive TH cells have recently been proposed to be responsible for autoimmune 
413 damage to CNS grey matter in the progressive stage of MS [26]. The possibility that EBNA1 
414 generated, βSYN-reactive TH cells induce additional autoimmune pathology, after the 
18
415 potential initiation of MS by molecular mimicry between MOG and HERV env proteins, 
416 therefore justifies investigation. There is long standing evidence for HLA DR2b-dependent 
417 molecular mimicry between MBP_3 and an EBV polymerase peptide [30, 37, 38]. Their HLA 
418 DR2b binding was again confirmed but their precise role in the aetiology of MS remains to 
419 be elucidated. 
420 Investigations on other pairs of potential HLA DR2b-binding peptides in EBNA1 
421 and a variety of CNS proteins observed in an independent study [32] may also be useful 
422 because our study was limited to CNS proteins with high encephalitogenic potential and 
423 constrained by the number of peptide pairs that could be tested for HLA DR2b binding. 
424 The HLA DR2a molecule is formed by pairing of the DRB5*0101 β chain variant, 
425 whose gene is closely linked to the DRB1*1501 gene in many individuals, with the relatively 
426 non-polymorphic DRA1*0101 α chain. The previous in silico based predictions failed to 
427 identify strong HLA DR2a binding pairs of potential sequence-related TH cell epitopes in 
428 HERV env and myelin proteins MBP, MOG and PLP [16]. However, because of the close 
429 genetic linkage of the two β chain loci, investigating potential HLA DR2a-binding TH epitopes 
430 in an extended set of encephalitogenic CNS proteins and EBV or HERV proteins is 
431 warranted because HLA DR2a and HLA DR2b molecules bind complementary sets of 
432 peptides through different binding motifs [56]. 
433
434 5. Conclusions
435 The results of the cell free HLA DR2b binding assays and molecular modelling 
436 show that sequence-related MOG and HERV env as well as βSYN and EBNA1 peptide 
437 pairs, with each set of pairs containing related potential TH epitopes, are able to bind to HLA 
438 DR2b with similar affinity and conformation to a peptide MBP_3 containing an experimentally 
439 confirmed TH epitope. Such pairs of sequence-related peptides are candidates for molecular 
440 mimicry in MS. However, definitive support for molecular mimicry will require detailed studies 
19
441 on CD4+ TH cell responses to the identified peptides. Such investigations may also contribute 
442 to the variety of immunomodulatory approaches presently being explored for treating MS 
443 [12, 24, 57 - 64]. 
444
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668 Figure 1 Comparison of the HLA DR2b-MBP_3 complex generated by HADDOCK 
669 with the reference structure. (A) Superposition of MBP_3 peptides bound to HLA 
670 DR2b in the reference (cyan) and modelled structures (black). (B) Ribbon 
671 representation of the published crystal structure of HLA DR2b bound to MBP peptide 
672 (MBP_3; ENPVVHFFKNIVTPR) (PDB entry 1YMM). (C) Ribbon representation of the 
673 lowest energy HLA DRb-MBP_3 complex model structure generated by HADDOCK. 
674 The HLA DR2b alpha and beta chains are depicted as pink and blue, respectively. For 
675 clarity only the peptide binding groove is highlighted. The peptide side chains (ball 
676 and stick format) and positions (red) are shown. Peptide residues P1, P4, P6 and P9 
677 serve as anchor residues which slot into the antigen binding groove, whereas side 
678 chains at P-1, P2, P5 and P8 are surface exposed. HLA DR2b residues involved in 
679 stabilising peptide binding are also highlighted (ball and stick format). The black 
680 rectangle boxes correspond to the core 9-mer sequence for each peptide. Figure was 
681 generated with Pymol (The PyMOL Molecular Graphics System, Version 1.8 
682 Schrödinger, LLC)
683
684 Figure 2 Comparison of HADDOCK generated models of HLA DR2b in complex with 
685 peptides derived from myelin (MOG) and HERV W-family (MSRVenv, SYN1 and 
686 SYN2) associated proteins. (A) Superposition of MOG_4 (red), MSRVenv_5 (blue), 
28
687 SYN1_2 (yellow) and SYN2_5 (green) peptides bound to HLA DR2b. (B) Ribbon 
688 representation of the lowest energy HLA DR2b-MOG_4 complex model structure. (C) 
689 Ribbon representation of the lowest energy HLA DRb-MSRV_5 complex model 
690 structure. (D) Ribbon representation of the lowest energy HLA DR2b-SYN1_2 
691 complex model structure. (E) Ribbon representation of the lowest energy HLA DRb-
692 SYN2_5 complex model structure. The HLA DR2b alpha and beta chains are 
693 depicted as pink and blue, respectively. For clarity only the peptide binding groove is 
694 highlighted. The peptide side chains (ball and stick format) and positions (red) are 
695 shown. Peptide residues P1, P4, P6 and P9 serve as anchor residues which insert 
696 into the antigen binding groove, whereas side chains at P-1, P2, P5 and P8 are 
697 surface exposed. HLA DR2b residues that contribute to peptide interactions are also 
698 highlighted (ball and stick format). The black rectangle boxes correspond to the core 
699 9-mer sequence for each peptide.  
700
701 Figure 3 Comparison of HADDOCK generated models of HLA DR2b in complex with 
702 peptides derived from a CNS (β-SYN) and an EBV (EBNA1) protein. (A) 
703 Superposition of βSYN (grey) and EBNA1_2 (orange) peptides bound to HLA DR2b. 
704 (B) Ribbon representation of the lowest energy HLA DR2b-βSYN complex model 
705 structure. (C) Ribbon representation of the lowest energy HLA DRb-EBNA1_2 
706 complex model structure. The HLA DR2b alpha and beta chains are depicted as pink 
707 and blue, respectively. For clarity only the peptide binding groove is highlighted. The 
708 peptide side chains (ball and stick format) and positions (red) are shown. Peptide 
709 residues P1, P4, P6 and P9 serve as anchor residues which slot into the antigen 
710 binding groove, whereas side chains at P-1, P2, P5 and P8 are surface exposed. HLA 
711 DR2b residues involved in peptide binding are also highlighted (ball and stick format). 
712 The black rectangle boxes correspond to the core 9-mer sequence for each peptide.  
713
HLA DR2b-MBP_3 complex structure (PDB entry 1YMM)
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HLA DR2b-MBP_3 complex model
P-4 P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1































HLA DR2b-MBP_3 complex 
Haddock score -163.7 ±1.6
HLA DR2b-MOG_4
P-5 P-4 P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1
I T L F V I V P V L G P L V AMOG_4
Position P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1 P+2 P+3






























HLA DR2b-SYN1_2 HLA DR2b-SYN2_5
D
P-5 P-4 P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1
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Haddock score -123.7 ±2.5 Haddock score -158.1 ±2.1
Haddock score -152.5 ±4.4 Haddock score -137.8 ±5.3
HLA-DR2b- -synuclein complex model
P-5 P-4 P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1
E K T K E G V L Y V G S K T R-synuclein
Position P-3 P-2 P-1 1 2 3 4 5 6 7 8 9 P+1 P+2 P+3
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Table S2. Region of sequence homology identified in BLASTp analysis of the selected 
CNS proteins against all non-redundant protein sequences in the EBV proteome taxid 
10377
1. ABP (Query) vs whole EBV PROTEOME (subject)
RecName: Full=Epstein-Barr nuclear antigen 4; Short=EBNA-4; Short=EBV nuclear antigen 
4; AltName: Full=Epstein-Barr nuclear antigen 3B; Short=EBNA-3B; Short=EBV nuclear 
antigen 3B 
Sequence ID: P03203.3Length: 938Number of Matches: 1
Related Information
Gene-associated gene details
Identical Proteins-Identical proteins to YP_401670.1
Range 1: 571 to 623GenPeptGraphics Next Match Previous Match 
Alignment statistics for match #1
Score Expect Method Identities Positives Gaps
22.3 bits(46) 0.95 Compositional matrix adjust. 17/53(32%) 25/53(47%) 2/53(3%)
Query  125  PADVDPLT--ITSSLSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK  
175
            P ++ PLT   TS LSS        P   V   +     T++ +P  TAAP++
Sbjct  571  PLEIQPLTSPTTSQLSSSAPSCAQTPWPVVQPSQTPDDPTKQSRPPETAAPRQ  
623
Table S3 – Regions of sequence homologies identified in BLASTp analysis of the 
selected CNS proteins against the three HERV env proteins MSRV env, SYN1 and 
SYN2
1. ABP (Query) vs SYN2 (Subject)
Score Expect Method Identities Positives Gaps
25.4 bits(54) 0.001 Composition-based stats. 18/53(34%) 26/53(49%) 7/53(13%)
Query  6    HHPWIHRPFFPFHSPSRLFDQFFGEHLLESDLF----PTSTSLSPFYLRPPSF  
54
            H+ + H+P FP   P+  F Q  G  L +S  F    P+S S   F+ RP  +
Sbjct  163  HNQFRHQPRFP-KPPNITFPQ--GTLLDKSSRFCQGRPSSCSTRNFWFRPADY  
21
2. ABP (Query) vs MSRV env (Subject)
Score Expect Method Identities Positives Gaps
16.9 bits(32) 0.50 Composition-based stats. 7/31(23%) 15/31(48%) 0/31(0%)
Query  116  REFHRKYRIPADVDPLTITSSLSSDGVLTVN  146
            +EF  + R+P ++D  +  S    +   T +
Sbjct  35   QEFLWRTRLPGNIDAPSYRSLSKGNSTFTAH  65
3. MAG (Query) vs MSRV env (Subject)
 
Score Expect Method Identities Positives Gaps
19.6 bits(39) 0.34 Compositional matrix adjust. 17/71(24%) 32/71(45%) 5/71(7%)
Query  142  
NIVVPPEVVAGTEVEVSCMVPDNCPELRPELSWLGHEGLGEPAVLGRLREDEGTWVQVSL  201
+ +VPP  +   +   + +VP    +  P L ++   G     VLGRL    G+    + 
Subject 291
SFLVPPMTIYTEQDLYNHVVPKPHNKRVPILPFVIRAG-----VLGRLGTGIGSITTSTQ  345
Table S4. Results of the IEDB analysis of the CNS proteins ABP, MAG, OSP and 
βSYN showing peptides with potential to bind HLA DR2b
1. ABP 
Start End Core nonamer 15mer peptide IC50 Percentile rank
9 23 FFPFHSPSR WIHRPFFPFHSPSRL 394 7.59
19 33 FDQFFGEHL SPSRLFDQFFGEHLL 409 7.88
21 35 FDQFFGEHL SRLFDQFFGEHLLES 423 8.16
20 34 FDQFFGEHL PSRLFDQFFGEHLLE 425 8.21
22 36 FDQFFGEHL RLFDQFFGEHLLESD 433 8.37
8 22 HRPFFPFHS PWIHRPFFPFHSPSR 449 8.69
42 56 FYLRPPSFL TSLSPFYLRPPSFLR 467 9.04
18 32 SRLFDQFFG HSPSRLFDQFFGEHL 483 9.37
10 24 FFPFHSPSR IHRPFFPFHSPSRLF 495 9.62
11 25 FFPFHSPSR HRPFFPFHSPSRLFD 511 9.96
43 57 YLRPPSFLR SLSPFYLRPPSFLRA 529 10.32
48 62 PSFLRAPSW YLRPPSFLRAPSWFD 554 10.83
12 26 FFPFHSPSR RPFFPFHSPSRLFDQ 573 11.17
44 58 YLRPPSFLR LSPFYLRPPSFLRAP 578 11.26
49 63 FLRAPSWFD LRPPSFLRAPSWFDT 600 11.68
46 60 YLRPPSFLR PFYLRPPSFLRAPSW 610 11.85
50 64 FLRAPSWFD RPPSFLRAPSWFDTG 628 12.18
5 19 WIHRPFFPF IHHPWIHRPFFPFHS 632 12.25
41 55 LSPFYLRPP STSLSPFYLRPPSFL 635 12.3
6 20 HRPFFPFHS HHPWIHRPFFPFHSP 645 12.48
45 59 YLRPPSFLR SPFYLRPPSFLRAPS 655 12.66
7 21 HRPFFPFHS HPWIHRPFFPFHSPS 662 12.78
128 142 LTITSSLSS VDPLTITSSLSSDGV 672 12.98
38 52 STSLSPFYL FPTSTSLSPFYLRPP 684 13.19
127 141 LTITSSLSS DVDPLTITSSLSSDG 703 13.53
125 139 PLTITSSLS PADVDPLTITSSLSS 707 13.61
126 140 LTITSSLSS ADVDPLTITSSLSSD 721 13.87
51 65 FLRAPSWFD PPSFLRAPSWFDTGL 740 14.21
52 66 FLRAPSWFD PSFLRAPSWFDTGLS 744 14.28
129 143 LTITSSLSS DPLTITSSLSSDGVL 754 14.45
39 53 STSLSPFYL PTSTSLSPFYLRPPS 755 14.46
35 49 TSTSLSPFY SDLFPTSTSLSPFYL 810 15.42
36 50 STSLSPFYL DLFPTSTSLSPFYLR 818 15.56
37 51 STSLSPFYL LFPTSTSLSPFYLRP 821 15.61
112 126 ISREFHRKY GFISREFHRKYRIPA 858 16.25
1 15 IAIHHPWIH MDIAIHHPWIHRPFF 865 16.35
47 61 PSFLRAPSW FYLRPPSFLRAPSWF 924 17.32
24 38 FDQFFGEHL FDQFFGEHLLESDLF 971 18.09
114 128 FHRKYRIPA ISREFHRKYRIPADV 988 18.37
139 153 VLTVNGPRK SDGVLTVNGPRKQVS 992 18.43
138 152 VLTVNGPRK SSDGVLTVNGPRKQV 993 18.45
40 54 LSPFYLRPP TSTSLSPFYLRPPSF 996 18.49
23 37 FDQFFGEHL LFDQFFGEHLLESDL 1006 18.62
137 151 VLTVNGPRK LSSDGVLTVNGPRKQ 1028 18.94
140 154 VLTVNGPRK DGVLTVNGPRKQVSG 1036 19.07
78 92 VKHFSPEEL NLDVKHFSPEELKVK 1041 19.14
113 127 FHRKYRIPA FISREFHRKYRIPAD 1043 19.17
77 91 VKHFSPEEL VNLDVKHFSPEELKV 1050 19.27
75 89 VNLDVKHFS FSVNLDVKHFSPEEL 1056 19.35
136 150 GVLTVNGPR SLSSDGVLTVNGPRK 1083 19.74
76 90 VKHFSPEEL SVNLDVKHFSPEELK 1109 20.1
79 93 VKHFSPEEL LDVKHFSPEELKVKV 1110 20.12
87 101 KVKVLGDVI EELKVKVLGDVIEVH 1153 20.74
86 100 KVKVLGDVI PEELKVKVLGDVIEV 1199 21.36
108 122 EHGFISREF QDEHGFISREFHRKY 1220 21.64
115 129 FHRKYRIPA SREFHRKYRIPADVD 1227 21.75
116 130 FHRKYRIPA REFHRKYRIPADVDP 1247 22.01
85 99 KVKVLGDVI SPEELKVKVLGDVIE 1262 22.21
13 27 FFPFHSPSR PFFPFHSPSRLFDQF 1273 22.36
84 98 LKVKVLGDV FSPEELKVKVLGDVI 1312 22.86
88 102 KVKVLGDVI ELKVKVLGDVIEVHG 1364 23.53
110 124 ISREFHRKY EHGFISREFHRKYRI 1364 23.53
131 145 LTITSSLSS LTITSSLSSDGVLTV 1399 23.96
130 144 LTITSSLSS PLTITSSLSSDGVLT 1491 25.07
14 28 FFPFHSPSR FFPFHSPSRLFDQFF 1601 26.35
2 16 IAIHHPWIH DIAIHHPWIHRPFFP 1626 26.64
111 125 REFHRKYRI HGFISREFHRKYRIP 1680 27.27
107 121 EHGFISREF RQDEHGFISREFHRK 1775 28.31
106 120 EHGFISREF ERQDEHGFISREFHR 1867 29.3
109 123 EHGFISREF DEHGFISREFHRKYR 1887 29.5
3 17 IAIHHPWIH IAIHHPWIHRPFFPF 1901 29.64
124 138 ADVDPLTIT IPADVDPLTITSSLS 1923 29.86
53 67 FLRAPSWFD SFLRAPSWFDTGLSE 2097 31.59
27 41 EHLLESDLF FFGEHLLESDLFPTS 2107 31.69
26 40 EHLLESDLF QFFGEHLLESDLFPT 2124 31.86
28 42 EHLLESDLF FGEHLLESDLFPTST 2218 32.72
65 79 MRLEKDRFS LSEMRLEKDRFSVNL 2262 33.12
105 119 EHGFISREF EERQDEHGFISREFH 2270 33.19
104 118 ERQDEHGFI HEERQDEHGFISREF 2391 34.24
66 80 MRLEKDRFS SEMRLEKDRFSVNLD 2453 34.76
25 39 EHLLESDLF DQFFGEHLLESDLFP 2459 34.8
89 103 KVKVLGDVI LKVKVLGDVIEVHGK 2475 34.94
34 48 LFPTSTSLS ESDLFPTSTSLSPFY 2502 35.15
132 146 TSSLSSDGV TITSSLSSDGVLTVN 2503 35.16
141 155 VLTVNGPRK GVLTVNGPRKQVSGP 2508 35.2
62 76 EMRLEKDRF DTGLSEMRLEKDRFS 2521 35.3
63 77 MRLEKDRFS TGLSEMRLEKDRFSV 2547 35.5
64 78 MRLEKDRFS GLSEMRLEKDRFSVN 2550 35.52
54 68 FLRAPSWFD FLRAPSWFDTGLSEM 2585 35.8
118 132 FHRKYRIPA FHRKYRIPADVDPLT 2634 36.2
71 85 DRFSVNLDV EKDRFSVNLDVKHFS 2651 36.33
117 131 FHRKYRIPA EFHRKYRIPADVDPL 2656 36.37
80 94 VKHFSPEEL DVKHFSPEELKVKVL 2763 37.2
67 81 MRLEKDRFS EMRLEKDRFSVNLDV 2806 37.51
68 82 DRFSVNLDV MRLEKDRFSVNLDVK 2840 37.76
15 29 FPFHSPSRL FPFHSPSRLFDQFFG 2871 37.98
142 156 VLTVNGPRK VLTVNGPRKQVSGPE 2928 38.41
81 95 VKHFSPEEL VKHFSPEELKVKVLG 2938 38.48
158 172 ITREEKPAV TIPITREEKPAVTAA 3023 39.08
157 171 ITREEKPAV RTIPITREEKPAVTA 3073 39.43
159 173 ITREEKPAV IPITREEKPAVTAAP 3073 39.43
156 170 ITREEKPAV ERTIPITREEKPAVT 3079 39.47
70 84 DRFSVNLDV LEKDRFSVNLDVKHF 3128 39.78
91 105 LGDVIEVHG VKVLGDVIEVHGKHE 3159 39.99
4 18 PWIHRPFFP AIHHPWIHRPFFPFH 3238 40.5
29 43 LLESDLFPT GEHLLESDLFPTSTS 3271 40.71
30 44 LLESDLFPT EHLLESDLFPTSTSL 3275 40.73
90 104 KVKVLGDVI KVKVLGDVIEVHGKH 3306 40.93
92 106 VIEVHGKHE KVLGDVIEVHGKHEE 3439 41.78
16 30 SRLFDQFFG PFHSPSRLFDQFFGE 3464 41.93
155 169 TIPITREEK PERTIPITREEKPAV 3538 42.38
69 83 DRFSVNLDV RLEKDRFSVNLDVKH 3626 42.89
17 31 SRLFDQFFG FHSPSRLFDQFFGEH 3666 43.13
72 86 VNLDVKHFS KDRFSVNLDVKHFSP 3945 44.7
133 147 LSSDGVLTV ITSSLSSDGVLTVNG 3947 44.71
83 97 PEELKVKVL HFSPEELKVKVLGDV 3958 44.77
73 87 VNLDVKHFS DRFSVNLDVKHFSPE 4002 45
93 107 VIEVHGKHE VLGDVIEVHGKHEER 4063 45.32
31 45 SDLFPTSTS HLLESDLFPTSTSLS 4159 45.81
94 108 VIEVHGKHE LGDVIEVHGKHEERQ 4206 46.05
59 73 FDTGLSEMR SWFDTGLSEMRLEKD 4301 46.55
32 46 SDLFPTSTS LLESDLFPTSTSLSP 4309 46.59
58 72 DTGLSEMRL PSWFDTGLSEMRLEK 4590 47.93
56 70 FDTGLSEMR RAPSWFDTGLSEMRL 4595 47.95
33 47 SDLFPTSTS LESDLFPTSTSLSPF 4685 48.37
57 71 FDTGLSEMR APSWFDTGLSEMRLE 4685 48.37
74 88 VNLDVKHFS RFSVNLDVKHFSPEE 4710 48.49
95 109 VIEVHGKHE GDVIEVHGKHEERQD 4806 48.91
135 149 LSSDGVLTV SSLSSDGVLTVNGPR 4809 48.92
134 148 TSSLSSDGV TSSLSSDGVLTVNGP 4948 49.55
2. MAG 
Start End Core Nonamer 15mer Peptide                   IC50    Percentile Rank
6 20 FWIMISASR ALPLFWIMISASRGG 120 1.64
7 21 FWIMISASR LPLFWIMISASRGGH 121 1.66
8 22 FWIMISASR PLFWIMISASRGGHW 126 1.75
1 15 MIFLTALPL MIFLTALPLFWIMIS 149 2.21
9 23 IMISASRGG LFWIMISASRGGHWG 160 2.44
5 19 FWIMISASR TALPLFWIMISASRG 164 2.52
520 534 FAILIAIVC VVAFAILIAIVCYIT 178 2.81
4 18 LTALPLFWI LTALPLFWIMISASR 183 2.92
521 535 LIAIVCYIT VAFAILIAIVCYITQ 187 3.02
10 24 IMISASRGG FWIMISASRGGHWGA 214 3.66
523 537 LIAIVCYIT FAILIAIVCYITQTR 221 3.8
53 67 VWYFNSPYP AVVHGVWYFNSPYPK 224 3.87
223 237 FEGYASMDV NTTLQFEGYASMDVK 225 3.89
464 478 GLVLTSILT ERSGLVLTSILTLRG 225 3.89
465 479 GLVLTSILT RSGLVLTSILTLRGQ 227 3.93
222 236 TLQFEGYAS PNTTLQFEGYASMDV 228 3.96
524 538 LIAIVCYIT AILIAIVCYITQTRR 228 3.96
354 368 LTIFKEKQI DPILTIFKEKQILST 229 3.98
522 536 LIAIVCYIT AFAILIAIVCYITQT 230 4
353 367 LTIFKEKQI PDPILTIFKEKQILS 232 4.04
52 66 GVWYFNSPY PAVVHGVWYFNSPYP 234 4.09
55 69 VWYFNSPYP VHGVWYFNSPYPKNY 237 4.16
352 366 LTIFKEKQI NPDPILTIFKEKQIL 238 4.19
224 238 FEGYASMDV TTLQFEGYASMDVKY 241 4.25
355 369 LTIFKEKQI PILTIFKEKQILSTV 241 4.25
54 68 VWYFNSPYP VVHGVWYFNSPYPKN 243 4.3
225 239 FEGYASMDV TLQFEGYASMDVKYP 247 4.39
351 365 ILTIFKEKQ SNPDPILTIFKEKQI 258 4.64
226 240 FEGYASMDV LQFEGYASMDVKYPP 260 4.69
411 425 VLLLESHCA FAPVLLLESHCAAAR 263 4.77
517 531 VVAFAILIA VGAVVAFAILIAIVC 266 4.83
412 426 VLLLESHCA APVLLLESHCAAARD 274 5.03
357 371 EKQILSTVI LTIFKEKQILSTVIY 275 5.05
518 532 FAILIAIVC GAVVAFAILIAIVCY 276 5.07
356 370 LTIFKEKQI ILTIFKEKQILSTVI 277 5.09
514 528 VGAVVAFAI IGPVGAVVAFAILIA 277 5.09
410 424 VLLLESHCA EFAPVLLLESHCAAA 278 5.11
515 529 VGAVVAFAI GPVGAVVAFAILIAI 279 5.14
409 423 VLLLESHCA VEFAPVLLLESHCAA 285 5.27
56 70 VWYFNSPYP HGVWYFNSPYPKNYP 287 5.31
97 111 CTLLLSNVS LRNCTLLLSNVSPEL 287 5.31
463 477 GLVLTSILT SERSGLVLTSILTLR 290 5.37
408 422 PVLLLESHC SVEFAPVLLLESHCA 292 5.41
98 112 CTLLLSNVS RNCTLLLSNVSPELG 302 5.63
462 476 GLVLTSILT YSERSGLVLTSILTL 303 5.66
166 180 LRPELSWLG PELRPELSWLGHEGL 308 5.78
131 145 LDIVNTPNI EHSVLDIVNTPNIVV 310 5.82
132 146 IVNTPNIVV HSVLDIVNTPNIVVP 316 5.96
162 176 ELRPELSWL PDNCPELRPELSWLG 317 5.98
163 177 LRPELSWLG DNCPELRPELSWLGH 320 6.04
164 178 LRPELSWLG NCPELRPELSWLGHE 322 6.08
94 108 LRNCTLLLS DLGLRNCTLLLSNVS 329 6.24
133 147 IVNTPNIVV SVLDIVNTPNIVVPP 329 6.24
2 16 LTALPLFWI IFLTALPLFWIMISA 331 6.29
165 179 LRPELSWLG CPELRPELSWLGHEG 333 6.34
466 480 LTSILTLRG SGLVLTSILTLRGQA 338 6.46
467 481 LTSILTLRG GLVLTSILTLRGQAQ 338 6.46
519 533 FAILIAIVC AVVAFAILIAIVCYI 342 6.54
95 109 CTLLLSNVS LGLRNCTLLLSNVSP 350 6.7
317 331 LSVMYAPWK TVGLSVMYAPWKPTV 352 6.74
318 332 LSVMYAPWK VGLSVMYAPWKPTVN 362 6.96
96 110 CTLLLSNVS GLRNCTLLLSNVSPE 368 7.08
246 260 VEAIEGSHV NSSVEAIEGSHVSLL 369 7.1
247 261 VEAIEGSHV SSVEAIEGSHVSLLC 376 7.24
359 373 EKQILSTVI IFKEKQILSTVIYES 383 7.37
358 372 EKQILSTVI TIFKEKQILSTVIYE 385 7.41
516 530 VVAFAILIA PVGAVVAFAILIAIV 385 7.41
316 330 LSVMYAPWK RTVGLSVMYAPWKPT 386 7.43
26 40 ISAFEGTCV MPSSISAFEGTCVSI 395 7.61
245 259 VEAIEGSHV MNSSVEAIEGSHVSL 400 7.71
28 42 ISAFEGTCV SSISAFEGTCVSIPC 401 7.73
27 41 ISAFEGTCV PSSISAFEGTCVSIP 403 7.76
468 482 ILTLRGQAQ LVLTSILTLRGQAQA 403 7.76
196 210 LLHFVPTRE WVQVSLLHFVPTREA 404 7.79
461 475 VYSERSGLV VYSERSGLVLTSILT 404 7.79
67 81 PVVFKSRTQ KNYPPVVFKSRTQVV 408 7.86
11 25 IMISASRGG WIMISASRGGHWGAW 410 7.9
25 39 ISAFEGTCV WMPSSISAFEGTCVS 410 7.9
68 82 PVVFKSRTQ NYPPVVFKSRTQVVH 411 7.92
24 38 PSSISAFEG AWMPSSISAFEGTCV 412 7.94
315 329 LSVMYAPWK NRTVGLSVMYAPWKP 413 7.96
487 501 RNLYGAKSL ICTARNLYGAKSLEL 415 8.01
69 83 PVVFKSRTQ YPPVVFKSRTQVVHE 420 8.1
134 148 IVNTPNIVV VLDIVNTPNIVVPPE 422 8.14
135 149 IVNTPNIVV LDIVNTPNIVVPPEV 428 8.26
488 502 RNLYGAKSL CTARNLYGAKSLELP 429 8.28
197 211 LHFVPTREA VQVSLLHFVPTREAN 434 8.39
244 258 VEAIEGSHV EMNSSVEAIEGSHVS 434 8.39
360 374 EKQILSTVI FKEKQILSTVIYESE 436 8.43
243 257 VEMNSSVEA VEMNSSVEAIEGSHV 440 8.51
489 503 RNLYGAKSL TARNLYGAKSLELPF 452 8.75
513 527 VGAVVAFAI KIGPVGAVVAFAILI 457 8.85
496 510 ELPFQGAHR AKSLELPFQGAHRLM 462 8.95
497 511 ELPFQGAHR KSLELPFQGAHRLMW 467 9.04
198 212 LHFVPTREA QVSLLHFVPTREANG 471 9.14
314 328 TVGLSVMYA DNRTVGLSVMYAPWK 472 9.15
495 509 ELPFQGAHR GAKSLELPFQGAHRL 482 9.36
525 539 LIAIVCYIT ILIAIVCYITQTRRK 488 9.48
228 242 FEGYASMDV FEGYASMDVKYPPVI 491 9.54
498 512 ELPFQGAHR SLELPFQGAHRLMWA 491 9.54
66 80 PVVFKSRTQ PKNYPPVVFKSRTQV 493 9.58
199 213 LHFVPTREA VSLLHFVPTREANGH 503 9.79
12 26 IMISASRGG IMISASRGGHWGAWM 507 9.87
456 470 VYSERSGLV SEREFVYSERSGLVL 509 9.92
512 526 VGAVVAFAI AKIGPVGAVVAFAIL 512 9.98
511 525 IGPVGAVVA WAKIGPVGAVVAFAI 521 10.16
238 252 IVEMNSSVE YPPVIVEMNSSVEAI 523 10.19
239 253 IVEMNSSVE PPVIVEMNSSVEAIE 526 10.26
526 540 LIAIVCYIT LIAIVCYITQTRRKK 529 10.32
405 419 LSVEFAPVL FNLSVEFAPVLLLES 533 10.41
403 417 LSVEFAPVL TAFNLSVEFAPVLLL 538 10.52
404 418 LSVEFAPVL AFNLSVEFAPVLLLE 541 10.58
3 17 LTALPLFWI FLTALPLFWIMISAS 546 10.68
611 625 LTEELAEYA YTLTEELAEYAEIRV 547 10.7
612 626 LAEYAEIRV TLTEELAEYAEIRVK 553 10.81
237 251 IVEMNSSVE KYPPVIVEMNSSVEA 556 10.87
236 250 VIVEMNSSV VKYPPVIVEMNSSVE 567 11.05
455 469 REFVYSERS ESEREFVYSERSGLV 569 11.09
485 499 ARNLYGAKS RVICTARNLYGAKSL 569 11.09
362 376 EKQILSTVI EKQILSTVIYESELQ 576 11.23
65 79 YPKNYPPVV YPKNYPPVVFKSRTQ 581 11.32
428 442 LCVVKSNPE VQCLCVVKSNPEPSV 583 11.36
457 471 VYSERSGLV EREFVYSERSGLVLT 603 11.73
458 472 VYSERSGLV REFVYSERSGLVLTS 605 11.76
57 71 VWYFNSPYP GVWYFNSPYPKNYPP 607 11.8
429 443 LCVVKSNPE QCLCVVKSNPEPSVA 607 11.8
195 209 VQVSLLHFV TWVQVSLLHFVPTRE 615 11.94
469 483 ILTLRGQAQ VLTSILTLRGQAQAP 619 12.02
402 416 LSVEFAPVL ATAFNLSVEFAPVLL 620 12.04
427 441 LCVVKSNPE TVQCLCVVKSNPEPS 627 12.17
99 113 CTLLLSNVS NCTLLLSNVSPELGG 631 12.23
470 484 ILTLRGQAQ LTSILTLRGQAQAPP 634 12.29
231 245 DVKYPPVIV YASMDVKYPPVIVEM 639 12.37
100 114 CTLLLSNVS CTLLLSNVSPELGGK 641 12.41
551 565 PVLFSSDFR GDNPPVLFSSDFRIS 646 12.5
425 439 VQCLCVVKS RDTVQCLCVVKSNPE 647 12.51
550 564 PVLFSSDFR AGDNPPVLFSSDFRI 647 12.51
229 243 MDVKYPPVI EGYASMDVKYPPVIV 651 12.59
130 144 LDIVNTPNI SEHSVLDIVNTPNIV 653 12.62
486 500 RNLYGAKSL VICTARNLYGAKSLE 653 12.62
504 518 HRLMWAKIG QGAHRLMWAKIGPVG 653 12.62
230 244 DVKYPPVIV GYASMDVKYPPVIVE 655 12.66
553 567 PVLFSSDFR NPPVLFSSDFRISGA 655 12.66
426 440 LCVVKSNPE DTVQCLCVVKSNPEP 660 12.74
552 566 PVLFSSDFR DNPPVLFSSDFRISG 664 12.82
503 517 HRLMWAKIG FQGAHRLMWAKIGPV 673 12.99
490 504 LYGAKSLEL ARNLYGAKSLELPFQ 680 13.12
319 333 LSVMYAPWK GLSVMYAPWKPTVNG 686 13.23
365 379 TVIYESELQ ILSTVIYESELQLEL 687 13.25
505 519 HRLMWAKIG GAHRLMWAKIGPVGA 698 13.43
363 377 TVIYESELQ KQILSTVIYESELQL 716 13.79
232 246 DVKYPPVIV ASMDVKYPPVIVEMN 718 13.82
200 214 LHFVPTREA SLLHFVPTREANGHR 720 13.85
491 505 LYGAKSLEL RNLYGAKSLELPFQG 722 13.88
129 143 VLDIVNTPN FSEHSVLDIVNTPNI 728 13.98
413 427 VLLLESHCA PVLLLESHCAAARDT 733 14.08
227 241 FEGYASMDV QFEGYASMDVKYPPV 736 14.14
366 380 TVIYESELQ LSTVIYESELQLELP 738 14.17
459 473 VYSERSGLV EFVYSERSGLVLTSI 740 14.21
168 182 LRPELSWLG LRPELSWLGHEGLGE 743 14.26
577 591 ERRLLGLRG LGSERRLLGLRGEPP 743 14.26
364 378 TVIYESELQ QILSTVIYESELQLE 744 14.28
115 129 FRGDLGGYN YYFRGDLGGYNQYTF 747 14.33
414 428 VLLLESHCA VLLLESHCAAARDTV 756 14.48
240 254 IVEMNSSVE PVIVEMNSSVEAIEG 757 14.5
578 592 ERRLLGLRG GSERRLLGLRGEPPE 761 14.56
167 181 LRPELSWLG ELRPELSWLGHEGLG 763 14.6
193 207 WVQVSLLHF EGTWVQVSLLHFVPT 773 14.78
501 515 AHRLMWAKI LPFQGAHRLMWAKIG 782 14.94
192 206 WVQVSLLHF DEGTWVQVSLLHFVP 802 15.26
194 208 WVQVSLLHF GTWVQVSLLHFVPTR 814 15.48
406 420 SVEFAPVLL NLSVEFAPVLLLESH 817 15.53
471 485 ILTLRGQAQ TSILTLRGQAQAPPR 831 15.78
494 508 AKSLELPFQ YGAKSLELPFQGAHR 844 16.02
191 205 WVQVSLLHF EDEGTWVQVSLLHFV 847 16.07
58 72 VWYFNSPYP VWYFNSPYPKNYPPV 854 16.18
508 522 WAKIGPVGA RLMWAKIGPVGAVVA 855 16.19
499 513 LPFQGAHRL LELPFQGAHRLMWAK 875 16.52
137 151 IVNTPNIVV IVNTPNIVVPPEVVA 878 16.57
89 103 LLGDLGLRN SRLLGDLGLRNCTLL 880 16.6
361 375 EKQILSTVI KEKQILSTVIYESEL 882 16.63
509 523 IGPVGAVVA LMWAKIGPVGAVVAF 887 16.71
320 334 LSVMYAPWK LSVMYAPWKPTVNGT 889 16.74
506 520 LMWAKIGPV AHRLMWAKIGPVGAV 897 16.88
70 84 PVVFKSRTQ PPVVFKSRTQVVHES 912 17.11
136 150 IVNTPNIVV DIVNTPNIVVPPEVV 913 17.13
71 85 PVVFKSRTQ PVVFKSRTQVVHESF 931 17.45
502 516 HRLMWAKIG PFQGAHRLMWAKIGP 941 17.61
507 521 LMWAKIGPV HRLMWAKIGPVGAVV 942 17.62
574 588 ERRLGSERR ERRLGSERRLLGLRG 946 17.68
88 102 LLGDLGLRN RSRLLGDLGLRNCTL 990 18.4
116 130 LGGYNQYTF YFRGDLGGYNQYTFS 990 18.4
117 131 LGGYNQYTF FRGDLGGYNQYTFSE 992 18.43
51 65 AVVHGVWYF RPAVVHGVWYFNSPY 1000 18.54
233 247 DVKYPPVIV SMDVKYPPVIVEMNS 1001 18.55
575 589 ERRLLGLRG RRLGSERRLLGLRGE 1003 18.58
248 262 VEAIEGSHV SVEAIEGSHVSLLCG 1008 18.65
500 514 ELPFQGAHR ELPFQGAHRLMWAKI 1012 18.71
101 115 LLSNVSPEL TLLLSNVSPELGGKY 1021 18.84
484 498 ICTARNLYG PRVICTARNLYGAKS 1031 18.99
549 563 SAGDNPPVL SAGDNPPVLFSSDFR 1046 19.22
579 593 LLGLRGEPP SERRLLGLRGEPPEL 1051 19.29
190 204 TWVQVSLLH REDEGTWVQVSLLHF 1058 19.39
332 346 MVAVEGETV NGTMVAVEGETVSIL 1078 19.67
249 263 VEAIEGSHV VEAIEGSHVSLLCGA 1079 19.69
510 524 IGPVGAVVA MWAKIGPVGAVVAFA 1079 19.69
554 568 VLFSSDFRI PPVLFSSDFRISGAP 1080 19.7
576 590 ERRLLGLRG RLGSERRLLGLRGEP 1081 19.71
401 415 TAFNLSVEF RATAFNLSVEFAPVL 1093 19.89
482 496 ICTARNLYG APPRVICTARNLYGA 1094 19.9
235 249 DVKYPPVIV DVKYPPVIVEMNSSV 1097 19.95
333 347 MVAVEGETV GTMVAVEGETVSILC 1101 19.99
580 594 LLGLRGEPP ERRLLGLRGEPPELD 1103 20.02
481 495 RVICTARNL QAPPRVICTARNLYG 1110 20.12
369 383 ELQLELPAV VIYESELQLELPAVS 1113 20.16
212 226 LGCQASFPN GHRLGCQASFPNTTL 1120 20.28
86 100 LLGDLGLRN QGRSRLLGDLGLRNC 1128 20.39
483 497 ICTARNLYG PPRVICTARNLYGAK 1131 20.43
340 354 VSILCSTQS GETVSILCSTQSNPD 1135 20.49
267 281 LTWMRDGTV PPPLLTWMRDGTVLR 1136 20.51
460 474 VYSERSGLV FVYSERSGLVLTSIL 1136 20.51
439 453 AFELPSRNV EPSVAFELPSRNVTV 1139 20.55
370 384 LQLELPAVS IYESELQLELPAVSP 1150 20.69
371 385 LQLELPAVS YESELQLELPAVSPE 1158 20.81
213 227 LGCQASFPN HRLGCQASFPNTTLQ 1161 20.85
220 234 TLQFEGYAS SFPNTTLQFEGYASM 1161 20.85
29 43 ISAFEGTCV SISAFEGTCVSIPCR 1166 20.92
30 44 ISAFEGTCV ISAFEGTCVSIPCRF 1176 21.05
407 421 LSVEFAPVL LSVEFAPVLLLESHC 1182 21.13
221 235 TLQFEGYAS FPNTTLQFEGYASMD 1184 21.16
331 345 MVAVEGETV VNGTMVAVEGETVSI 1186 21.19
118 132 LGGYNQYTF RGDLGGYNQYTFSEH 1188 21.21
91 105 LLGDLGLRN LLGDLGLRNCTLLLS 1192 21.26
372 386 LQLELPAVS ESELQLELPAVSPED 1193 21.28
268 282 LTWMRDGTV PPLLTWMRDGTVLRE 1194 21.29
85 99 SRLLGDLGL FQGRSRLLGDLGLRN 1205 21.44
341 355 VSILCSTQS ETVSILCSTQSNPDP 1206 21.45
440 454 AFELPSRNV PSVAFELPSRNVTVN 1212 21.53
87 101 LLGDLGLRN GRSRLLGDLGLRNCT 1229 21.77
269 283 LTWMRDGTV PLLTWMRDGTVLREA 1231 21.8
329 343 VNGTMVAVE PTVNGTMVAVEGETV 1255 22.12
330 344 MVAVEGETV TVNGTMVAVEGETVS 1256 22.14
438 452 AFELPSRNV PEPSVAFELPSRNVT 1264 22.24
338 352 VSILCSTQS VEGETVSILCSTQSN 1268 22.28
47 61 PDELRPAVV PDELRPAVVHGVWYF 1269 22.3
337 351 TVSILCSTQ AVEGETVSILCSTQS 1272 22.35
339 353 VSILCSTQS EGETVSILCSTQSNP 1291 22.59
373 387 LQLELPAVS SELQLELPAVSPEDD 1312 22.86
581 595 LLGLRGEPP RRLLGLRGEPPELDL 1317 22.92
472 486 ILTLRGQAQ SILTLRGQAQAPPRV 1322 22.99
119 133 LGGYNQYTF GDLGGYNQYTFSEHS 1324 23.02
441 455 AFELPSRNV SVAFELPSRNVTVNE 1329 23.09
111 125 KYYFRGDLG LGGKYYFRGDLGGYN 1348 23.33
437 451 VAFELPSRN NPEPSVAFELPSRNV 1356 23.43
90 104 LLGDLGLRN RLLGDLGLRNCTLLL 1359 23.46
473 487 GQAQAPPRV ILTLRGQAQAPPRVI 1379 23.71
241 255 IVEMNSSVE VIVEMNSSVEAIEGS 1395 23.91
201 215 LHFVPTREA LLHFVPTREANGHRL 1402 24
431 445 LCVVKSNPE LCVVKSNPEPSVAFE 1404 24.02
430 444 LCVVKSNPE CLCVVKSNPEPSVAF 1411 24.11
49 63 AVVHGVWYF ELRPAVVHGVWYFNS 1415 24.16
50 64 AVVHGVWYF LRPAVVHGVWYFNSP 1450 24.57
138 152 PNIVVPPEV VNTPNIVVPPEVVAG 1503 25.21
454 468 REFVYSERS NESEREFVYSERSGL 1508 25.27
527 541 IVCYITQTR IAIVCYITQTRRKKN 1529 25.51
139 153 PNIVVPPEV NTPNIVVPPEVVAGT 1546 25.71
112 126 FRGDLGGYN GGKYYFRGDLGGYNQ 1559 25.86
219 233 TTLQFEGYA ASFPNTTLQFEGYAS 1607 26.42
480 494 RVICTARNL AQAPPRVICTARNLY 1667 27.11
114 128 FRGDLGGYN KYYFRGDLGGYNQYT 1676 27.23
367 381 TVIYESELQ STVIYESELQLELPA 1693 27.4
556 570 VLFSSDFRI VLFSSDFRISGAPEK 1700 27.48
48 62 AVVHGVWYF DELRPAVVHGVWYFN 1706 27.55
210 224 LGCQASFPN ANGHRLGCQASFPNT 1712 27.61
209 223 GHRLGCQAS EANGHRLGCQASFPN 1734 27.86
271 285 WMRDGTVLR LTWMRDGTVLREAVA 1738 27.9
572 586 ERRLGSERR ESERRLGSERRLLGL 1743 27.96
312 326 TVGLSVMYA GQDNRTVGLSVMYAP 1753 28.07
265 279 PPPLLTWMR SNPPPLLTWMRDGTV 1766 28.21
571 585 ERRLGSERR YESERRLGSERRLLG 1769 28.24
311 325 DNRTVGLSV YGQDNRTVGLSVMYA 1777 28.34
266 280 LTWMRDGTV NPPPLLTWMRDGTVL 1799 28.58
555 569 PVLFSSDFR PVLFSSDFRISGAPE 1802 28.61
92 106 DLGLRNCTL LGDLGLRNCTLLLSN 1811 28.71
113 127 FRGDLGGYN GKYYFRGDLGGYNQY 1811 28.71
102 116 LLSNVSPEL LLLSNVSPELGGKYY 1874 29.37
211 225 LGCQASFPN NGHRLGCQASFPNTT 1891 29.54
214 228 QASFPNTTL RLGCQASFPNTTLQF 1895 29.59
570 584 ERRLGSERR KYESERRLGSERRLL 1902 29.65
234 248 DVKYPPVIV MDVKYPPVIVEMNSS 1908 29.7
368 382 TVIYESELQ TVIYESELQLELPAV 1908 29.7
215 229 QASFPNTTL LGCQASFPNTTLQFE 1926 29.89
60 74 YPKNYPPVV YFNSPYPKNYPPVVF 1962 30.26
270 284 WMRDGTVLR LLTWMRDGTVLREAV 1973 30.36
121 135 LGGYNQYTF LGGYNQYTFSEHSVL 1982 30.45
61 75 YPKNYPPVV FNSPYPKNYPPVVFK 2012 30.73
474 488 GQAQAPPRV LTLRGQAQAPPRVIC 2038 31
313 327 TVGLSVMYA QDNRTVGLSVMYAPW 2045 31.06
589 603 LDLSYSHSD EPPELDLSYSHSDLG 2060 31.2
569 583 ERRLGSERR EKYESERRLGSERRL 2078 31.39
93 107 GLRNCTLLL GDLGLRNCTLLLSNV 2106 31.68
493 507 LYGAKSLEL LYGAKSLELPFQGAH 2111 31.73
202 216 LHFVPTREA LHFVPTREANGHRLG 2117 31.78
62 76 YPKNYPPVV NSPYPKNYPPVVFKS 2126 31.88
557 571 FRISGAPEK LFSSDFRISGAPEKY 2130 31.92
282 296 EAVAESLLL EAVAESLLLELEEVT 2157 32.17
559 573 FRISGAPEK SSDFRISGAPEKYES 2163 32.23
63 77 YPKNYPPVV SPYPKNYPPVVFKSR 2169 32.28
558 572 FRISGAPEK FSSDFRISGAPEKYE 2171 32.3
591 605 LSYSHSDLG PELDLSYSHSDLGKR 2194 32.51
108 122 GKYYFRGDL SPELGGKYYFRGDLG 2198 32.54
284 298 LLLELEEVT VAESLLLELEEVTPA 2207 32.62
479 493 PRVICTARN QAQAPPRVICTARNL 2214 32.68
285 299 LLLELEEVT AESLLLELEEVTPAE 2231 32.83
19 33 GAWMPSSIS GGHWGAWMPSSISAF 2239 32.91
109 123 KYYFRGDLG PELGGKYYFRGDLGG 2240 32.92
590 604 LSYSHSDLG PPELDLSYSHSDLGK 2241 32.93
21 35 GAWMPSSIS HWGAWMPSSISAFEG 2243 32.94
20 34 GAWMPSSIS GHWGAWMPSSISAFE 2269 33.18
103 117 LLSNVSPEL LLSNVSPELGGKYYF 2271 33.19
283 297 LLLELEEVT AVAESLLLELEEVTP 2284 33.31
59 73 WYFNSPYPK WYFNSPYPKNYPPVV 2291 33.37
140 154 NIVVPPEVV TPNIVVPPEVVAGTE 2298 33.43
568 582 YESERRLGS PEKYESERRLGSERR 2324 33.66
321 335 YAPWKPTVN SVMYAPWKPTVNGTM 2326 33.68
251 265 HVSLLCGAD AIEGSHVSLLCGADS 2348 33.87
528 542 VCYITQTRR AIVCYITQTRRKKNV 2348 33.87
492 506 LYGAKSLEL NLYGAKSLELPFQGA 2349 33.88
286 300 LLLELEEVT ESLLLELEEVTPAED 2351 33.89
120 134 LGGYNQYTF DLGGYNQYTFSEHSV 2354 33.92
254 268 VSLLCGADS GSHVSLLCGADSNPP 2369 34.05
529 543 IVCYITQTR IVCYITQTRRKKNVT 2387 34.21
252 266 VSLLCGADS IEGSHVSLLCGADSN 2397 34.29
342 356 VSILCSTQS TVSILCSTQSNPDPI 2419 34.47
343 357 VSILCSTQS VSILCSTQSNPDPIL 2434 34.61
442 456 AFELPSRNV VAFELPSRNVTVNES 2455 34.77
453 467 REFVYSERS VNESEREFVYSERSG 2478 34.96
475 489 GQAQAPPRV TLRGQAQAPPRVICT 2487 35.03
255 269 VSLLCGADS SHVSLLCGADSNPPP 2488 35.04
253 267 VSLLCGADS EGSHVSLLCGADSNP 2505 35.18
536 550 KNVTESPSF TRRKKNVTESPSFSA 2527 35.35
560 574 FRISGAPEK SDFRISGAPEKYESE 2541 35.46
110 124 KYYFRGDLG ELGGKYYFRGDLGGY 2564 35.64
537 551 VTESPSFSA RRKKNVTESPSFSAG 2605 35.97
78 92 HESFQGRSR TQVVHESFQGRSRLL 2623 36.11
476 490 GQAQAPPRV LRGQAQAPPRVICTA 2627 36.14
79 93 HESFQGRSR QVVHESFQGRSRLLG 2641 36.26
452 466 VNESEREFV TVNESEREFVYSERS 2669 36.47
538 552 VTESPSFSA RKKNVTESPSFSAGD 2679 36.56
123 137 YTFSEHSVL GYNQYTFSEHSVLDI 2721 36.87
592 606 LSYSHSDLG ELDLSYSHSDLGKRP 2736 37
18 32 GAWMPSSIS RGGHWGAWMPSSISA 2813 37.56
44 58 PDELRPAVV FDFPDELRPAVVHGV 2833 37.71
45 59 PDELRPAVV DFPDELRPAVVHGVW 2866 37.95
122 136 YTFSEHSVL GGYNQYTFSEHSVLD 2875 38.01
80 94 HESFQGRSR VVHESFQGRSRLLGD 2889 38.12
242 256 IVEMNSSVE IVEMNSSVEAIEGSH 2913 38.3
17 31 WGAWMPSSI SRGGHWGAWMPSSIS 2935 38.46
276 290 LREAVAESL DGTVLREAVAESLLL 2940 38.49
83 97 RSRLLGDLG ESFQGRSRLLGDLGL 2970 38.72
588 602 LDLSYSHSD GEPPELDLSYSHSDL 2982 38.8
77 91 HESFQGRSR RTQVVHESFQGRSRL 2984 38.81
277 291 LREAVAESL GTVLREAVAESLLLE 2984 38.81
13 27 ISASRGGHW MISASRGGHWGAWMP 2994 38.88
322 336 WKPTVNGTM VMYAPWKPTVNGTMV 2999 38.91
539 553 VTESPSFSA KKNVTESPSFSAGDN 3009 38.99
443 457 AFELPSRNV AFELPSRNVTVNESE 3039 39.19
350 364 PDPILTIFK QSNPDPILTIFKEKQ 3070 39.41
334 348 MVAVEGETV TMVAVEGETVSILCS 3071 39.42
393 407 ENQYGQRAT VAENQYGQRATAFNL 3087 39.52
530 544 YITQTRRKK VCYITQTRRKKNVTE 3099 39.59
610 624 LTEELAEYA SYTLTEELAEYAEIR 3118 39.72
335 349 MVAVEGETV MVAVEGETVSILCST 3131 39.8
540 554 VTESPSFSA KNVTESPSFSAGDNP 3153 39.95
278 292 LREAVAESL TVLREAVAESLLLEL 3164 40.02
128 142 HSVLDIVNT TFSEHSVLDIVNTPN 3166 40.03
14 28 ISASRGGHW ISASRGGHWGAWMPS 3177 40.1
582 596 LLGLRGEPP RLLGLRGEPPELDLS 3180 40.12
593 607 LSYSHSDLG LDLSYSHSDLGKRPT 3216 40.35
82 96 SFQGRSRLL HESFQGRSRLLGDLG 3228 40.43
275 289 LREAVAESL RDGTVLREAVAESLL 3275 40.73
273 287 GTVLREAVA WMRDGTVLREAVAES 3287 40.81
22 36 WMPSSISAF WGAWMPSSISAFEGT 3293 40.85
392 406 AENQYGQRA CVAENQYGQRATAFN 3307 40.93
299 313 VYACLAENA EDGVYACLAENAYGQ 3322 41.02
105 119 VSPELGGKY SNVSPELGGKYYFRG 3325 41.04
124 138 YTFSEHSVL YNQYTFSEHSVLDIV 3330 41.07
84 98 SRLLGDLGL SFQGRSRLLGDLGLR 3371 41.34
436 450 SVAFELPSR SNPEPSVAFELPSRN 3381 41.4
274 288 GTVLREAVA MRDGTVLREAVAESL 3383 41.41
300 314 VYACLAENA DGVYACLAENAYGQD 3388 41.45
76 90 QVVHESFQG SRTQVVHESFQGRSR 3405 41.57
216 230 QASFPNTTL GCQASFPNTTLQFEG 3416 41.63
272 286 GTVLREAVA TWMRDGTVLREAVAE 3446 41.82
573 587 ERRLGSERR SERRLGSERRLLGLR 3472 41.98
141 155 PNIVVPPEV PNIVVPPEVVAGTEV 3542 42.41
374 388 LQLELPAVS ELQLELPAVSPEDDG 3543 42.41
64 78 PKNYPPVVF PYPKNYPPVVFKSRT 3544 42.42
298 312 VYACLAENA AEDGVYACLAENAYG 3548 42.44
107 121 LGGKYYFRG VSPELGGKYYFRGDL 3589 42.68
395 409 GQRATAFNL ENQYGQRATAFNLSV 3600 42.74
391 405 AENQYGQRA WCVAENQYGQRATAF 3613 42.82
23 37 WMPSSISAF GAWMPSSISAFEGTC 3636 42.96
394 408 GQRATAFNL AENQYGQRATAFNLS 3639 42.97
125 139 YTFSEHSVL NQYTFSEHSVLDIVN 3659 43.1
609 623 LTEELAEYA DSYTLTEELAEYAEI 3698 43.32
43 57 PDELRPAVV RFDFPDELRPAVVHG 3724 43.47
81 95 SFQGRSRLL VHESFQGRSRLLGDL 3739 43.56
308 322 AYGQDNRTV ENAYGQDNRTVGLSV 3743 43.57
607 621 SYTLTEELA TKDSYTLTEELAEYA 3752 43.64
297 311 VYACLAENA PAEDGVYACLAENAY 3774 43.77
310 324 DNRTVGLSV AYGQDNRTVGLSVMY 3795 43.89
608 622 LTEELAEYA KDSYTLTEELAEYAE 3812 43.98
583 597 LLGLRGEPP LLGLRGEPPELDLSY 3849 44.18
41 55 RFDFPDELR PCRFDFPDELRPAVV 3865 44.27
397 411 GQRATAFNL QYGQRATAFNLSVEF 3867 44.28
42 56 PDELRPAVV CRFDFPDELRPAVVH 3895 44.42
542 556 VTESPSFSA VTESPSFSAGDNPPV 3906 44.48
104 118 VSPELGGKY LSNVSPELGGKYYFR 3918 44.55
169 183 LSWLGHEGL RPELSWLGHEGLGEP 3981 44.89
73 87 VFKSRTQVV VFKSRTQVVHESFQG 3982 44.89
189 203 LREDEGTWV LREDEGTWVQVSLLH 3984 44.91
279 293 EAVAESLLL VLREAVAESLLLELE 4013 45.06
375 389 LQLELPAVS LQLELPAVSPEDDGE 4027 45.14
170 184 LSWLGHEGL PELSWLGHEGLGEPA 4070 45.36
544 558 FSAGDNPPV ESPSFSAGDNPPVLF 4138 45.7
545 559 FSAGDNPPV SPSFSAGDNPPVLFS 4203 46.04
389 403 AENQYGQRA EYWCVAENQYGQRAT 4245 46.25
46 60 LRPAVVHGV FPDELRPAVVHGVWY 4256 46.31
546 560 FSAGDNPPV PSFSAGDNPPVLFSS 4259 46.32
543 557 FSAGDNPPV TESPSFSAGDNPPVL 4294 46.51
562 576 FRISGAPEK FRISGAPEKYESERR 4316 46.62
478 492 GQAQAPPRV GQAQAPPRVICTARN 4319 46.64
587 601 PELDLSYSH RGEPPELDLSYSHSD 4333 46.7
396 410 GQRATAFNL NQYGQRATAFNLSVE 4346 46.76
323 337 WKPTVNGTM MYAPWKPTVNGTMVA 4407 47.06
531 545 QTRRKKNVT CYITQTRRKKNVTES 4501 47.5
280 294 EAVAESLLL LREAVAESLLLELEE 4555 47.76
106 120 LGGKYYFRG NVSPELGGKYYFRGD 4619 48.06
172 186 WLGHEGLGE LSWLGHEGLGEPAVL 4684 48.37
309 323 DNRTVGLSV NAYGQDNRTVGLSVM 4770 48.75
325 339 WKPTVNGTM APWKPTVNGTMVAVE 4792 48.85
432 446 VKSNPEPSV CVVKSNPEPSVAFEL 4836 49.05
324 338 WKPTVNGTM YAPWKPTVNGTMVAV 4847 49.09
75 89 QVVHESFQG KSRTQVVHESFQGRS 4902 49.35
532 546 QTRRKKNVT YITQTRRKKNVTESP 4941 49.52
399 413 TAFNLSVEF GQRATAFNLSVEFAP 4975 49.67
257 271 VSLLCGADS VSLLCGADSNPPPLL 4996 49.77
3. OSP 
Start End Core Nonamer 15mer Peptide                                      IC50  Percentile Rank
123 137 LLILLALCA AGVLLILLALCALVA                                  33      0.2
124 138 LLILLALCA GVLLILLALCALVAT 34 0.21
122 136 LLILLALCA LAGVLLILLALCALV 35 0.23
121 135 LLILLALCA QLAGVLLILLALCAL 39 0.28
120 134 LAGVLLILL AQLAGVLLILLALCA 42 0.33
66 80 ILILPGYVQ KPLVDILILPGYVQA 56 0.52
68 82 ILILPGYVQ LVDILILPGYVQACR 56 0.52
67 81 ILILPGYVQ PLVDILILPGYVQAC 57 0.54
65 79 DILILPGYV CKPLVDILILPGYVQ 58 0.56
125 139 LLILLALCA VLLILLALCALVATI 69 0.73
69 83 ILILPGYVQ VDILILPGYVQACRA 70 0.75
126 140 LLILLALCA LLILLALCALVATIW 74 0.81
86 100 VLGLPAILL IAASVLGLPAILLLL 96 1.2
87 101 VLGLPAILL AASVLGLPAILLLLT 96 1.2
88 102 VLGLPAILL ASVLGLPAILLLLTV 100 1.27
85 99 VLGLPAILL MIAASVLGLPAILLL 104 1.35
84 98 SVLGLPAIL LMIAASVLGLPAILL 111 1.48
6 20 VVGFVTSFV LQVVGFVTSFVGWIG 114 1.54
5 19 VVGFVTSFV CLQVVGFVTSFVGWI 118 1.61
3 17 VVGFVTSFV ATCLQVVGFVTSFVG 123 1.69
4 18 VVGFVTSFV TCLQVVGFVTSFVGW 126 1.75
127 141 LLALCALVA LILLALCALVATIWF 144 2.11
190 204 LRALAPRLM STTLRALAPRLMRRV 149 2.21
150 164 VSFGYSLYA TIVSFGYSLYAGWIG 159 2.42
189 203 LRALAPRLM VSTTLRALAPRLMRR 159 2.42
188 202 LRALAPRLM NVSTTLRALAPRLMR 164 2.52
187 201 TLRALAPRL ENVSTTLRALAPRLM 169 2.62
2 16 CLQVVGFVT VATCLQVVGFVTSFV 172 2.68
70 84 ILILPGYVQ DILILPGYVQACRAL 173 2.71
7 21 VGFVTSFVG QVVGFVTSFVGWIGV 177 2.79
191 205 LRALAPRLM TTLRALAPRLMRRVP 179 2.83
90 104 VLGLPAILL VLGLPAILLLLTVLP 185 2.97
153 167 YSLYAGWIG SFGYSLYAGWIGAVL 185 2.97
154 168 YSLYAGWIG FGYSLYAGWIGAVLC 196 3.26
152 166 YSLYAGWIG VSFGYSLYAGWIGAV 197 3.28
64 78 VDILILPGY HCKPLVDILILPGYV 198 3.31
151 165 YSLYAGWIG IVSFGYSLYAGWIGA 199 3.33
71 85 ILILPGYVQ ILILPGYVQACRALM 203 3.42
89 103 VLGLPAILL SVLGLPAILLLLTVL 212 3.61
79 93 LMIAASVLG QACRALMIAASVLGL 220 3.78
80 94 LMIAASVLG ACRALMIAASVLGLP 224 3.87
78 92 ALMIAASVL VQACRALMIAASVLG 225 3.89
81 95 LMIAASVLG CRALMIAASVLGLPA 234 4.09
9 23 VTSFVGWIG VGFVTSFVGWIGVIV 252 4.51
146 160 IVSFGYSLY HRETTIVSFGYSLYA 252 4.51
8 22 VTSFVGWIG VVGFVTSFVGWIGVI 256 4.59
92 106 ILLLLTVLP GLPAILLLLTVLPCI 267 4.86
93 107 ILLLLTVLP LPAILLLLTVLPCIR 268 4.88
94 108 ILLLLTVLP PAILLLLTVLPCIRM 269 4.91
147 161 VSFGYSLYA RETTIVSFGYSLYAG 273 5.01
82 96 LMIAASVLG RALMIAASVLGLPAI 276 5.07
148 162 VSFGYSLYA ETTIVSFGYSLYAGW 280 5.16
129 143 LLALCALVA LLALCALVATIWFPV 300 5.59
128 142 LLALCALVA ILLALCALVATIWFP 303 5.66
10 24 VTSFVGWIG GFVTSFVGWIGVIVT 307 5.76
116 130 RRAQLAGVL KYRRAQLAGVLLILL 307 5.76
149 163 VSFGYSLYA TTIVSFGYSLYAGWI 309 5.8
91 105 ILLLLTVLP LGLPAILLLLTVLPC 316 5.96
119 133 LAGVLLILL RAQLAGVLLILLALC 322 6.08
118 132 LAGVLLILL RRAQLAGVLLILLAL 352 6.74
117 131 LAGVLLILL YRRAQLAGVLLILLA 360 6.92
192 206 LRALAPRLM TLRALAPRLMRRVPT 370 7.12
77 91 RALMIAASV YVQACRALMIAASVL 380 7.32
195 209 LMRRVPTYK ALAPRLMRRVPTYKR 381 7.34
196 210 MRRVPTYKR LAPRLMRRVPTYKRA 382 7.35
95 109 LTVLPCIRM AILLLLTVLPCIRMG 393 7.57
193 207 LRALAPRLM LRALAPRLMRRVPTY 406 7.82
96 110 LLLTVLPCI ILLLLTVLPCIRMGQ 425 8.21
197 211 MRRVPTYKR APRLMRRVPTYKRAA 425 8.21
198 212 MRRVPTYKR PRLMRRVPTYKRAAR 432 8.35
155 169 YSLYAGWIG GYSLYAGWIGAVLCL 454 8.78
145 159 ETTIVSFGY AHRETTIVSFGYSLY 465 9.01
156 170 YSLYAGWIG YSLYAGWIGAVLCLV 470 9.11
76 90 VQACRALMI GYVQACRALMIAASV 477 9.26
199 213 MRRVPTYKR RLMRRVPTYKRAARL 482 9.36
11 25 FVGWIGVIV FVTSFVGWIGVIVTT 488 9.48
12 26 FVGWIGVIV VTSFVGWIGVIVTTS 510 9.94
13 27 FVGWIGVIV TSFVGWIGVIVTTST 521 10.16
130 144 LCALVATIW LALCALVATIWFPVC 526 10.26
112 126 VAKYRRAQL PGVAKYRRAQLAGVL 550 10.75
194 208 LAPRLMRRV RALAPRLMRRVPTYK 560 10.94
72 86 YVQACRALM LILPGYVQACRALMI 562 10.98
83 97 LMIAASVLG ALMIAASVLGLPAIL 568 11.07
74 88 VQACRALMI LPGYVQACRALMIAA 571 11.13
73 87 VQACRALMI ILPGYVQACRALMIA 598 11.64
75 89 VQACRALMI PGYVQACRALMIAAS 601 11.69
161 175 VLCLVGGCV GWIGAVLCLVGGCVI 608 11.82
113 127 RRAQLAGVL GVAKYRRAQLAGVLL 635 12.3
114 128 RRAQLAGVL VAKYRRAQLAGVLLI 652 12.6
115 129 RRAQLAGVL AKYRRAQLAGVLLIL 671 12.96
162 176 VLCLVGGCV WIGAVLCLVGGCVIL 722 13.88
42 56 LDELGSKGL RKLDELGSKGLWADC 724 13.91
41 55 LDELGSKGL CRKLDELGSKGLWAD 733 14.08
40 54 LDELGSKGL TCRKLDELGSKGLWA 734 14.09
97 111 LTVLPCIRM LLLLTVLPCIRMGQE 742 14.24
163 177 VLCLVGGCV IGAVLCLVGGCVILC 744 14.28
131 145 LVATIWFPV ALCALVATIWFPVCA 753 14.43
38 52 IPTCRKLDE IPTCRKLDELGSKGL 758 14.51
39 53 LDELGSKGL PTCRKLDELGSKGLW 776 14.84
132 146 LVATIWFPV LCALVATIWFPVCAH 792 15.1
160 174 IGAVLCLVG AGWIGAVLCLVGGCV 799 15.21
14 28 IGVIVTTST SFVGWIGVIVTTSTN 800 15.23
1 15 CLQVVGFVT MVATCLQVVGFVTSF 820 15.59
164 178 VLCLVGGCV GAVLCLVGGCVILCC 842 15.98
186 200 TTLRALAPR GENVSTTLRALAPRL 853 16.16
133 147 LVATIWFPV CALVATIWFPVCAHR 879 16.59
157 171 YAGWIGAVL SLYAGWIGAVLCLVG 888 16.73
201 215 MRRVPTYKR MRRVPTYKRAARLPT 896 16.86
15 29 IGVIVTTST FVGWIGVIVTTSTND 932 17.47
200 214 MRRVPTYKR LMRRVPTYKRAARLP 932 17.47
111 125 VAKYRRAQL EPGVAKYRRAQLAGV 942 17.62
63 77 LVDILILPG YHCKPLVDILILPGY 968 18.04
144 158 ETTIVSFGY CAHRETTIVSFGYSL 1011 18.69
109 123 VAKYRRAQL GQEPGVAKYRRAQLA 1044 19.19
98 112 LTVLPCIRM LLLTVLPCIRMGQEP 1045 19.2
110 124 VAKYRRAQL QEPGVAKYRRAQLAG 1078 19.67
27 41 WVVTCGYTI TNDWVVTCGYTIPTC 1112 20.15
26 40 WVVTCGYTI STNDWVVTCGYTIPT 1127 20.37
28 42 WVVTCGYTI NDWVVTCGYTIPTCR 1185 21.17
24 38 DWVVTCGYT TTSTNDWVVTCGYTI 1195 21.31
25 39 WVVTCGYTI TSTNDWVVTCGYTIP 1201 21.39
57 71 GLYHCKPLV VMATGLYHCKPLVDI 1286 22.52
56 70 GLYHCKPLV CVMATGLYHCKPLVD 1301 22.71
108 122 EPGVAKYRR MGQEPGVAKYRRAQL 1320 22.96
158 172 IGAVLCLVG LYAGWIGAVLCLVGG 1325 23.03
16 30 IGVIVTTST VGWIGVIVTTSTNDW 1345 23.29
58 72 GLYHCKPLV MATGLYHCKPLVDIL 1368 23.58
17 31 IGVIVTTST GWIGVIVTTSTNDWV 1410 24.1
44 58 LDELGSKGL LDELGSKGLWADCVM 1458 24.67
159 173 IGAVLCLVG YAGWIGAVLCLVGGC 1465 24.75
204 218 YKRAARLPT VPTYKRAARLPTEVL 1484 24.99
55 69 TGLYHCKPL DCVMATGLYHCKPLV 1488 25.03
43 57 LDELGSKGL KLDELGSKGLWADCV 1490 25.06
59 73 GLYHCKPLV ATGLYHCKPLVDILI 1500 25.17
62 76 CKPLVDILI LYHCKPLVDILILPG 1534 25.57
165 179 LCLVGGCVI AVLCLVGGCVILCCA 1605 26.4
202 216 PTYKRAARL RRVPTYKRAARLPTE 1618 26.54
134 148 LVATIWFPV ALVATIWFPVCAHRE 1685 27.32
203 217 PTYKRAARL RVPTYKRAARLPTEV 1774 28.3
54 68 CVMATGLYH ADCVMATGLYHCKPL 1775 28.31
135 149 LVATIWFPV LVATIWFPVCAHRET 1847 29.09
143 157 ETTIVSFGY VCAHRETTIVSFGYS 1923 29.86
60 74 CKPLVDILI TGLYHCKPLVDILIL 2020 30.82
18 32 IVTTSTNDW WIGVIVTTSTNDWVV 2111 31.73
142 156 AHRETTIVS PVCAHRETTIVSFGY 2214 32.68
19 33 IVTTSTNDW IGVIVTTSTNDWVVT 2238 32.9
166 180 VLCLVGGCV VLCLVGGCVILCCAG 2379 34.14
52 66 VMATGLYHC LWADCVMATGLYHCK 2423 34.51
46 60 SKGLWADCV ELGSKGLWADCVMAT 2430 34.57
47 61 SKGLWADCV LGSKGLWADCVMATG 2469 34.88
51 65 CVMATGLYH GLWADCVMATGLYHC 2478 34.96
100 114 LTVLPCIRM LTVLPCIRMGQEPGV 2556 35.58
30 44 WVVTCGYTI WVVTCGYTIPTCRKL 2607 35.98
99 113 LTVLPCIRM LLTVLPCIRMGQEPG 2693 36.66
29 43 WVVTCGYTI DWVVTCGYTIPTCRK 2751 37.11
179 193 AQAFGENVS AGDAQAFGENVSTTL 2802 37.48
53 67 VMATGLYHC WADCVMATGLYHCKP 2849 37.82
180 194 AQAFGENVS GDAQAFGENVSTTLR 2850 37.83
61 75 CKPLVDILI GLYHCKPLVDILILP 3061 39.35
20 34 IVTTSTNDW GVIVTTSTNDWVVTC 3095 39.56
103 117 IRMGQEPGV LPCIRMGQEPGVAKY 3189 40.17
102 116 IRMGQEPGV VLPCIRMGQEPGVAK 3214 40.33
45 59 SKGLWADCV DELGSKGLWADCVMA 3217 40.35
101 115 IRMGQEPGV TVLPCIRMGQEPGVA 3307 40.93
50 64 LWADCVMAT KGLWADCVMATGLYH 3519 42.27
104 118 IRMGQEPGV PCIRMGQEPGVAKYR 3577 42.61
183 197 FGENVSTTL QAFGENVSTTLRALA 3684 43.24
185 199 VSTTLRALA FGENVSTTLRALAPR 3829 44.08
49 63 SKGLWADCV SKGLWADCVMATGLY 3928 44.6
182 196 FGENVSTTL AQAFGENVSTTLRAL 3933 44.63
137 151 IWFPVCAHR ATIWFPVCAHRETTI 4087 45.45
181 195 FGENVSTTL DAQAFGENVSTTLRA 4188 45.96
48 62 SKGLWADCV GSKGLWADCVMATGL 4576 47.86
171 185 VILCCAGDA GGCVILCCAGDAQAF 4598 47.96
184 198 VSTTLRALA AFGENVSTTLRALAP 4650 48.2
170 184 VILCCAGDA VGGCVILCCAGDAQA 4672 48.31
178 192 AQAFGENVS CAGDAQAFGENVSTT 4681 48.35
169 183 VILCCAGDA LVGGCVILCCAGDAQ 4806 48.91
177 191 AQAFGENVS CCAGDAQAFGENVST 4833 49.04
168 182 CVILCCAGD CLVGGCVILCCAGDA 4882 49.26
4. βSYN 
Start End Core Nonamer 15mer Peptide                        IC50      Percentile Rank
34 48 VLYVGSKTR KEGVLYVGSKTREGV 279 5.14
31 45 GVLYVGSKT EKTKEGVLYVGSKTR 284 5.24
32 46 VLYVGSKTR KTKEGVLYVGSKTRE 285 5.27
33 47 VLYVGSKTR TKEGVLYVGSKTREG 286 5.29
35 49 VLYVGSKTR EGVLYVGSKTREGVV 377 7.26
2 16 FMKGLSMAK DVFMKGLSMAKEGVV 702 13.51
36 50 VLYVGSKTR GVLYVGSKTREGVVQ 762 14.58
1 15 FMKGLSMAK MDVFMKGLSMAKEGV 780 14.91
30 44 AEKTKEGVL AEKTKEGVLYVGSKT 851 16.13
3 17 LSMAKEGVV VFMKGLSMAKEGVVA 1081 19.71
37 51 VLYVGSKTR VLYVGSKTREGVVQG 1136 20.51
4 18 LSMAKEGVV FMKGLSMAKEGVVAA 1396 23.93
5 19 LSMAKEGVV MKGLSMAKEGVVAAA 1596 26.3
6 20 LSMAKEGVV KGLSMAKEGVVAAAE 1953 30.17
45 59 VQGVASVAE REGVVQGVASVAEKT 2593 35.87
1 15 GNIAAATGL FSGAGNIAAATGLVK 2608 35.99
46 60 VQGVASVAE EGVVQGVASVAEKTK 2635 36.21
44 58 VQGVASVAE TREGVVQGVASVAEK 2649 36.32
2 16 IAAATGLVK SGAGNIAAATGLVKR 2662 36.42
43 57 VVQGVASVA KTREGVVQGVASVAE 2687 36.62
10 24 LVKREEFPT ATGLVKREEFPTDLK 2836 37.73
7 21 IAAATGLVK IAAATGLVKREEFPT 2844 37.79
3 17 IAAATGLVK GAGNIAAATGLVKRE 2846 37.8
9 23 LVKREEFPT AATGLVKREEFPTDL 2882 38.07
11 25 LVKREEFPT TGLVKREEFPTDLKP 2920 38.35
56 70 TKEQASHLG AEKTKEQASHLGGAV 2947 38.54
47 61 VQGVASVAE GVVQGVASVAEKTKE 3034 39.15
8 22 LVKREEFPT AAATGLVKREEFPTD 3111 39.67
4 18 IAAATGLVK AGNIAAATGLVKREE 3198 40.23
5 19 IAAATGLVK GNIAAATGLVKREEF 3733 43.52
53 67 KTKEQASHL ASVAEKTKEQASHLG 3969 44.82
55 69 TKEQASHLG VAEKTKEQASHLGGA 4011 45.06
7 21 LSMAKEGVV GLSMAKEGVVAAAEK 4041 45.21
54 68 TKEQASHLG SVAEKTKEQASHLGG 4080 45.42
42 56 GVVQGVASV SKTREGVVQGVASVA 4342 46.75
8 22 LSMAKEGVV LSMAKEGVVAAAEKT 4662 48.26
Legend to Table S4
The analysis of binding of the peptides to HLA DR2b was done using the Immune Epitope Data Base or IEDB 
(www. iedb.org). The default peptide length of 15 amino acids was used in the analysis but the sequence of 
the core nonamer peptide that is expected to bind to the HLA DR molecule and constitute the major portion of 
the T cell epitope is shown (column 3) for each 15 mer sequence (column 4). The starting and ending amino 
acid residue number for each nonamer in the protein sequence are shown in columns 1 and 2 respectively. The 
analysis was done using the Stabilised Matrix Method (SMM) where the peptides are ranked according to their 
predicted binding affinities or IC50 (column 5) which indicates the concentration of peptide in nM expected to 
achieve 50% saturation of the HLA DR molecule. Therefore a lower IC50 shows a higher affinity. As a guide, 
peptides with IC50 values <50 nM are considered to bind with high affinity, between 50nM to 500 nM with 
intermediate affinity and between 500nM to 5000 nM with low affinity. For each peptide, a percentile rank 
(columns 6) is generated by comparing the peptide's score against the scores of five million random 15 mers 
selected from the SWISSPROT protein database. Therefore smaller percentile rank values, typically <10, also 
indicate higher affinity and specificity of binding to the HLA DR molecule.
Table S5. Results of the IEDB analysis of EBNA1 and EBNA4 showing peptides 
with potential to bind HLA DR2b
1. EBNA1 
Start End Core nonamer 15mer peptide IC50 Percentile rank
558 572 FMVFLQTHI IVCYFMVFLQTHIFA 90 1.08
557 571 FMVFLQTHI SIVCYFMVFLQTHIF 91 1.1
559 573 FMVFLQTHI VCYFMVFLQTHIFAE 91 1.1
556 570 IVCYFMVFL ESIVCYFMVFLQTHI 97 1.21
560 574 FMVFLQTHI CYFMVFLQTHIFAEV 97 1.21
561 575 FMVFLQTHI YFMVFLQTHIFAEVL 197 3.28
562 576 FMVFLQTHI FMVFLQTHIFAEVLK 248 4.41
480 494 LRALLARSH NIAEGLRALLARSHV 288 5.34
482 496 LRALLARSH AEGLRALLARSHVER 306 5.73
579 593 LVMTKPAPT IKDLVMTKPAPTCNI 317 5.98
481 495 LRALLARSH IAEGLRALLARSHVE 318 6
483 497 LRALLARSH EGLRALLARSHVERT 323 6.11
479 493 AEGLRALLA ENIAEGLRALLARSH 326 6.18
576 590 IKDLVMTKP KDAIKDLVMTKPAPT 327 6.2
577 591 LVMTKPAPT DAIKDLVMTKPAPTC 331 6.29
580 594 LVMTKPAPT KDLVMTKPAPTCNIR 332 6.31
578 592 LVMTKPAPT AIKDLVMTKPAPTCN 336 6.41
554 568 IVCYFMVFL LRESIVCYFMVFLQT 390 7.51
553 567 IVCYFMVFL PLRESIVCYFMVFLQ 393 7.57
504 518 VFVYGGSKT VAGVFVYGGSKTSLY 410 7.9
503 517 VFVYGGSKT WVAGVFVYGGSKTSL 429 8.28
555 569 IVCYFMVFL RESIVCYFMVFLQTH 448 8.67
502 516 VFVYGGSKT TWVAGVFVYGGSKTS 451 8.73
505 519 VFVYGGSKT AGVFVYGGSKTSLYN 488 9.48
501 515 GVFVYGGSK GTWVAGVFVYGGSKT 549 10.73
552 566 ESIVCYFMV GPLRESIVCYFMVFL 649 12.55
484 498 LRALLARSH GLRALLARSHVERTT 661 12.76
514 528 YNLRRGTAL KTSLYNLRRGTALAI 675 13.03
515 529 YNLRRGTAL TSLYNLRRGTALAIP 695 13.39
512 526 TSLYNLRRG GSKTSLYNLRRGTAL 752 14.41
563 577 MVFLQTHIF MVFLQTHIFAEVLKD 805 15.33
516 530 YNLRRGTAL SLYNLRRGTALAIPQ 808 15.38
506 520 FVYGGSKTS GVFVYGGSKTSLYNL 815 15.5
513 527 YNLRRGTAL SKTSLYNLRRGTALA 823 15.64
485 499 LRALLARSH LRALLARSHVERTTD 863 16.32
581 595 LVMTKPAPT DLVMTKPAPTCNIRV 940 17.59
582 596 LVMTKPAPT LVMTKPAPTCNIRVT 969 18.06
530 544 LTPLSRLPF QCRLTPLSRLPFGMA 1059 19.4
531 545 LTPLSRLPF CRLTPLSRLPFGMAP 1088 19.81
564 578 THIFAEVLK VFLQTHIFAEVLKDA 1196 21.32
507 521 VFVYGGSKT VFVYGGSKTSLYNLR 1242 21.95
517 531 LRRGTALAI LYNLRRGTALAIPQC 1272 22.35
565 579 THIFAEVLK FLQTHIFAEVLKDAI 1283 22.49
478 492 AEGLRALLA FENIAEGLRALLARS 1344 23.28
476 490 IAEGLRALL PKFENIAEGLRALLA 1378 23.7
511 525 KTSLYNLRR GGSKTSLYNLRRGTA 1404 24.02
477 491 AEGLRALLA KFENIAEGLRALLAR 1427 24.29
518 532 LRRGTALAI YNLRRGTALAIPQCR 1444 24.5
529 543 LTPLSRLPF PQCRLTPLSRLPFGM 1487 25.02
566 580 THIFAEVLK LQTHIFAEVLKDAIK 1542 25.66
527 541 QCRLTPLSR AIPQCRLTPLSRLPF 1565 25.92
510 524 KTSLYNLRR YGGSKTSLYNLRRGT 1574 26.03
528 542 LTPLSRLPF IPQCRLTPLSRLPFG 1576 26.05
508 522 YGGSKTSLY FVYGGSKTSLYNLRR 1592 26.24
509 523 KTSLYNLRR VYGGSKTSLYNLRRG 1595 26.29
532 546 LSRLPFGMA RLTPLSRLPFGMAPG 1617 26.53
533 547 LSRLPFGMA LTPLSRLPFGMAPGP 1671 27.16
520 534 LRRGTALAI LRRGTALAIPQCRLT 2020 30.82
500 514 VAGVFVYGG EGTWVAGVFVYGGSK 2092 31.54
534 548 LSRLPFGMA TPLSRLPFGMAPGPG 2223 32.76
551 565 ESIVCYFMV PGPLRESIVCYFMVF 2330 33.72
568 582 FAEVLKDAI THIFAEVLKDAIKDL 2494 35.09
522 536 LAIPQCRLT RGTALAIPQCRLTPL 2558 35.6
524 538 LAIPQCRLT TALAIPQCRLTPLSR 2593 35.87
523 537 LAIPQCRLT GTALAIPQCRLTPLS 2699 36.71
567 581 FAEVLKDAI QTHIFAEVLKDAIKD 2708 36.77
550 564 RESIVCYFM QPGPLRESIVCYFMV 2781 37.33
475 489 ENIAEGLRA NPKFENIAEGLRALL 2853 37.86
498 512 GTWVAGVFV TDEGTWVAGVFVYGG 2881 38.06
486 500 RALLARSHV RALLARSHVERTTDE 2939 38.48
499 513 GTWVAGVFV DEGTWVAGVFVYGGS 2971 38.72
535 549 RLPFGMAPG PLSRLPFGMAPGPGP 3084 39.5
521 535 LAIPQCRLT RRGTALAIPQCRLTP 3122 39.74
536 550 RLPFGMAPG LSRLPFGMAPGPGPQ 3146 39.9
569 583 FAEVLKDAI HIFAEVLKDAIKDLV 3170 40.06
525 539 QCRLTPLSR ALAIPQCRLTPLSRL 3239 40.5
519 533 LRRGTALAI NLRRGTALAIPQCRL 3305 40.92
526 540 QCRLTPLSR LAIPQCRLTPLSRLP 3531 42.34
400 414 RRPFFHPVG PGRRPFFHPVGEADY 4096 45.5
474 488 ENIAEGLRA SNPKFENIAEGLRAL 4105 45.54
497 511 GTWVAGVFV TTDEGTWVAGVFVYG 4179 45.91
549 563 PGPLRESIV PQPGPLRESIVCYFM 4196 46
570 584 VLKDAIKDL IFAEVLKDAIKDLVM 4211 46.08
496 510 GTWVAGVFV RTTDEGTWVAGVFVY 4241 46.23
600 614 GVDLPPWFP FDDGVDLPPWFPPMV 4300 46.54
574 588 KDAIKDLVM VLKDAIKDLVMTKPA 4302 46.55
601 615 LPPWFPPMV DDGVDLPPWFPPMVE 4424 47.14
571 585 VLKDAIKDL FAEVLKDAIKDLVMT 4429 47.17
455 469 GRRKKGGWF DGGRRKKGGWFGKHR 4460 47.31
495 509 TTDEGTWVA ERTTDEGTWVAGVFV 4737 48.61
459 473 KGGWFGKHR RKKGGWFGKHRGQGG 4772 48.76
572 586 VLKDAIKDL AEVLKDAIKDLVMTK 4888 49.29
473 487 FENIAEGLR GSNPKFENIAEGLRA 4988 49.72
2.  EBNA4 
 
Start End Core Nonamer 15mer Peptide IC50 Percentile Rank
117 131 DLRPLGSLF SMLQSDLRPLGSLFL 67 0.7
118 132 LRPLGSLFL MLQSDLRPLGSLFLE 68 0.72
119 133 LRPLGSLFL LQSDLRPLGSLFLEQ 68 0.72
120 134 LRPLGSLFL QSDLRPLGSLFLEQN 69 0.73
121 135 LRPLGSLFL SDLRPLGSLFLEQNL 72 0.78
123 137 LRPLGSLFL LRPLGSLFLEQNLNI 162 2.48
156 170 IVKQRRWKL KKPLPIVKQRRWKLL 177 2.79
157 171 IVKQRRWKL KPLPIVKQRRWKLLS 178 2.81
680 694 LLRQWAPAT GPATMLLRQWAPATM 189 3.07
682 696 LLRQWAPAT ATMLLRQWAPATMQT 189 3.07
681 695 LLRQWAPAT PATMLLRQWAPATMQ 190 3.11
159 173 IVKQRRWKL LPIVKQRRWKLLSSC 193 3.18
158 172 IVKQRRWKL PLPIVKQRRWKLLSS 196 3.26
155 169 LPIVKQRRW RKKPLPIVKQRRWKL 200 3.35
683 697 LLRQWAPAT TMLLRQWAPATMQTP 200 3.35
122 136 LRPLGSLFL DLRPLGSLFLEQNLN 201 3.38
679 693 TMLLRQWAP TGPATMLLRQWAPAT 203 3.42
164 178 WKLLSSCRS QRRWKLLSSCRSWRM 209 3.53
624 638 LRPIPMRPL WPMPLRPIPMRPLRM 210 3.56
626 640 LRPIPMRPL MPLRPIPMRPLRMQP 211 3.58
625 639 LRPIPMRPL PMPLRPIPMRPLRMQ 212 3.61
571 585 IQPLTSPTT PLEIQPLTSPTTSQL 221 3.8
572 586 IQPLTSPTT LEIQPLTSPTTSQLS 222 3.82
570 584 IQPLTSPTT DPLEIQPLTSPTTSQ 235 4.12
165 179 LSSCRSWRM RRWKLLSSCRSWRMG 236 4.14
568 582 EIQPLTSPT GPDPLEIQPLTSPTT 236 4.14
569 583 IQPLTSPTT PDPLEIQPLTSPTTS 236 4.14
623 637 LRPIPMRPL QWPMPLRPIPMRPLR 237 4.16
622 636 PMPLRPIPM RQWPMPLRPIPMRPL 241 4.25
768 782 LRQLLTGGV TKQILRQLLTGGVKK 257 4.62
234 248 TAFLMARRA KIETAFLMARRARSL 265 4.81
767 781 LRQLLTGGV PTKQILRQLLTGGVK 266 4.83
769 783 LRQLLTGGV KQILRQLLTGGVKKG 266 4.83
766 780 ILRQLLTGG GPTKQILRQLLTGGV 270 4.94
235 249 LMARRARSL IETAFLMARRARSLS 274 5.03
161 175 IVKQRRWKL IVKQRRWKLLSSCRS 278 5.11
770 784 LRQLLTGGV QILRQLLTGGVKKGR 292 5.41
236 250 LMARRARSL ETAFLMARRARSLSA 318 6
166 180 LSSCRSWRM RWKLLSSCRSWRMGY 320 6.04
237 251 LMARRARSL TAFLMARRARSLSAE 320 6.04
167 181 LSSCRSWRM WKLLSSCRSWRMGYR 333 6.34
628 642 LRPIPMRPL LRPIPMRPLRMQPIP 362 6.96
253 267 FDLVSSGNT YTLFFDLVSSGNTLY 364 7
627 641 LRPIPMRPL PLRPIPMRPLRMQPI 364 7
254 268 FDLVSSGNT TLFFDLVSSGNTLYA 367 7.05
238 252 LMARRARSL AFLMARRARSLSAER 377 7.26
255 269 FDLVSSGNT LFFDLVSSGNTLYAI 380 7.32
251 265 YTLFFDLVS ERYTLFFDLVSSGNT 398 7.67
631 645 MRPLRMQPI IPMRPLRMQPIPFNH 406 7.82
168 182 LSSCRSWRM KLLSSCRSWRMGYRT 409 7.88
630 644 MRPLRMQPI PIPMRPLRMQPIPFN 409 7.88
276 290 FIEFVGWLC KNRVSFIEFVGWLCK 410 7.9
105 119 VIQLVHAVY APVIQLVHAVYDSML 411 7.92
252 266 FDLVSSGNT RYTLFFDLVSSGNTL 416 8.03
277 291 FIEFVGWLC NRVSFIEFVGWLCKK 419 8.08
629 643 MRPLRMQPI RPIPMRPLRMQPIPF 424 8.18
811 825 APIFYPPVL DKIVQAPIFYPPVLQ 434 8.39
813 827 APIFYPPVL IVQAPIFYPPVLQPI 444 8.59
278 292 FIEFVGWLC RVSFIEFVGWLCKKD 445 8.61
275 289 RVSFIEFVG TKNRVSFIEFVGWLC 454 8.78
160 174 IVKQRRWKL PIVKQRRWKLLSSCR 460 8.91
810 824 KIVQAPIFY SDKIVQAPIFYPPVL 460 8.91
279 293 FIEFVGWLC VSFIEFVGWLCKKDH 466 9.02
148 162 AIRKKPLPI RHRCQAIRKKPLPIV 473 9.17
812 826 APIFYPPVL KIVQAPIFYPPVLQP 473 9.17
149 163 IRKKPLPIV HRCQAIRKKPLPIVK 476 9.24
814 828 APIFYPPVL VQAPIFYPPVLQPIQ 487 9.46
163 177 WKLLSSCRS KQRRWKLLSSCRSWR 516 10.06
233 247 TAFLMARRA QKIETAFLMARRARS 530 10.34
684 698 LLRQWAPAT MLLRQWAPATMQTPP 532 10.38
106 120 VHAVYDSML PVIQLVHAVYDSMLQ 547 10.7
162 176 WKLLSSCRS VKQRRWKLLSSCRSW 548 10.72
261 275 GNTLYAIWI SSGNTLYAIWIGLGT 548 10.72
104 118 VIQLVHAVY QAPVIQLVHAVYDSM 551 10.77
103 117 VIQLVHAVY TQAPVIQLVHAVYDS 563 10.99
102 116 VIQLVHAVY PTQAPVIQLVHAVYD 564 11.01
515 529 VMATLLPPV VMEQRVMATLLPPVP 565 11.02
257 271 LVSSGNTLY FDLVSSGNTLYAIWI 574 11.19
150 164 AIRKKPLPI RCQAIRKKPLPIVKQ 575 11.21
151 165 IRKKPLPIV CQAIRKKPLPIVKQR 586 11.41
264 278 YAIWIGLGT NTLYAIWIGLGTKNR 590 11.48
231 245 ETAFLMARR QNQKIETAFLMARRA 610 11.85
265 279 WIGLGTKNR TLYAIWIGLGTKNRV 610 11.85
685 699 LLRQWAPAT LLRQWAPATMQTPPR 623 12.1
232 246 TAFLMARRA NQKIETAFLMARRAR 634 12.29
514 528 EQRVMATLL EVMEQRVMATLLPPV 642 12.43
516 530 VMATLLPPV MEQRVMATLLPPVPQ 651 12.59
517 531 VMATLLPPV EQRVMATLLPPVPQQ 651 12.59
573 587 IQPLTSPTT EIQPLTSPTTSQLSS 657 12.69
260 274 GNTLYAIWI VSSGNTLYAIWIGLG 663 12.8
633 647 PLRMQPIPF MRPLRMQPIPFNHPV 663 12.8
518 532 VMATLLPPV QRVMATLLPPVPQQP 668 12.89
656 670 ITPYKPTWA QVEITPYKPTWAQIG 669 12.91
574 588 IQPLTSPTT IQPLTSPTTSQLSSS 670 12.93
632 646 PLRMQPIPF PMRPLRMQPIPFNHP 679 13.1
655 669 ITPYKPTWA PQVEITPYKPTWAQI 685 13.21
657 671 ITPYKPTWA VEITPYKPTWAQIGH 691 13.32
771 785 LRQLLTGGV ILRQLLTGGVKKGRP 691 13.32
267 281 WIGLGTKNR YAIWIGLGTKNRVSF 693 13.35
266 280 WIGLGTKNR LYAIWIGLGTKNRVS 698 13.43
653 667 VEITPYKPT QTPQVEITPYKPTWA 717 13.8
654 668 ITPYKPTWA TPQVEITPYKPTWAQ 722 13.88
262 276 YAIWIGLGT SGNTLYAIWIGLGTK 728 13.98
107 121 VHAVYDSML VIQLVHAVYDSMLQS 731 14.04
259 273 GNTLYAIWI LVSSGNTLYAIWIGL 736 14.14
263 277 YAIWIGLGT GNTLYAIWIGLGTKN 736 14.14
256 270 FDLVSSGNT FFDLVSSGNTLYAIW 742 14.24
268 282 WIGLGTKNR AIWIGLGTKNRVSFI 760 14.55
239 253 LMARRARSL FLMARRARSLSAERY 761 14.56
809 823 DKIVQAPIF TSDKIVQAPIFYPPV 780 14.91
414 428 IVTDFSVIK RAIVTDFSVIKAIEE 788 15.04
101 115 PVIQLVHAV NPTQAPVIQLVHAVY 789 15.06
772 786 LRQLLTGGV LRQLLTGGVKKGRPS 791 15.08
258 272 GNTLYAIWI DLVSSGNTLYAIWIG 794 15.12
807 821 DKIVQAPIF SGTSDKIVQAPIFYP 794 15.12
475 489 WQPLPGPQV LEPWQPLPGPQVTAV 811 15.43
808 822 DKIVQAPIF GTSDKIVQAPIFYPP 811 15.43
806 820 DKIVQAPIF GSGTSDKIVQAPIFY 826 15.69
765 779 KQILRQLLT QGPTKQILRQLLTGG 833 15.82
472 486 LEPWQPLPG QARLEPWQPLPGPQV 844 16.02
473 487 WQPLPGPQV ARLEPWQPLPGPQVT 846 16.06
153 167 IRKKPLPIV AIRKKPLPIVKQRRW 848 16.08
147 161 CQAIRKKPL VRHRCQAIRKKPLPI 855 16.19
240 254 LMARRARSL LMARRARSLSAERYT 856 16.21
474 488 WQPLPGPQV RLEPWQPLPGPQVTA 857 16.23
476 490 WQPLPGPQV EPWQPLPGPQVTAVL 860 16.27
888 902 VVILENVGQ SHSPVVILENVGQGQ 860 16.27
108 122 VHAVYDSML IQLVHAVYDSMLQSD 861 16.29
666 680 HIPYQPTPT WAQIGHIPYQPTPTG 863 16.32
889 903 VVILENVGQ HSPVVILENVGQGQQ 865 16.35
781 795 SLKLQAALE KKGRPSLKLQAALER 874 16.5
887 901 VVILENVGQ ASHSPVVILENVGQG 875 16.52
886 900 PVVILENVG GASHSPVVILENVGQ 876 16.53
783 797 LKLQAALER GRPSLKLQAALERQA 892 16.78
824 838 VMGQGGSPT LQPIQVMGQGGSPTA 902 16.96
447 461 VVLQRPPTQ SQAPTVVLQRPPTQQ 911 17.1
446 460 TVVLQRPPT ESQAPTVVLQRPPTQ 912 17.11
782 796 LKLQAALER KGRPSLKLQAALERQ 916 17.19
448 462 VVLQRPPTQ QAPTVVLQRPPTQQE 917 17.21
784 798 LKLQAALER RPSLKLQAALERQAA 920 17.26
815 829 APIFYPPVL QAPIFYPPVLQPIQV 921 17.27
823 837 IQVMGQGGS VLQPIQVMGQGGSPT 922 17.29
124 138 LFLEQNLNI RPLGSLFLEQNLNIE 925 17.35
665 679 IGHIPYQPT TWAQIGHIPYQPTPT 926 17.36
449 463 VVLQRPPTQ APTVVLQRPPTQQEP 927 17.38
411 425 IVTDFSVIK KKCRAIVTDFSVIKA 930 17.43
125 139 LFLEQNLNI PLGSLFLEQNLNIEE 932 17.47
152 166 IRKKPLPIV QAIRKKPLPIVKQRR 932 17.47
825 839 VMGQGGSPT QPIQVMGQGGSPTAM 933 17.49
412 426 IVTDFSVIK KCRAIVTDFSVIKAI 935 17.52
667 681 HIPYQPTPT AQIGHIPYQPTPTGP 942 17.62
827 841 VMGQGGSPT IQVMGQGGSPTAMAA 962 17.95
154 168 LPIVKQRRW IRKKPLPIVKQRRWK 975 18.16
109 123 VHAVYDSML QLVHAVYDSMLQSDL 977 18.19
826 840 VMGQGGSPT PIQVMGQGGSPTAMA 977 18.19
785 799 LKLQAALER PSLKLQAALERQAAA 992 18.43
97 111 VNPTQAPVI FVDVNPTQAPVIQLV 1017 18.78
170 184 LSSCRSWRM LSSCRSWRMGYRTHN 1038 19.1
169 183 LSSCRSWRM LLSSCRSWRMGYRTH 1040 19.13
890 904 VVILENVGQ SPVVILENVGQGQQQ 1044 19.19
787 801 LKLQAALER LKLQAALERQAAAGW 1047 19.23
336 350 AMNIEAPRL YARGQAMNIEAPRLP 1048 19.25
174 188 RMGYRTHNL RSWRMGYRTHNLKVN 1056 19.35
413 427 IVTDFSVIK CRAIVTDFSVIKAIE 1059 19.4
98 112 VNPTQAPVI VDVNPTQAPVIQLVH 1063 19.46
96 110 VNPTQAPVI RFVDVNPTQAPVIQL 1065 19.48
126 140 LFLEQNLNI LGSLFLEQNLNIEEF 1065 19.48
173 187 RMGYRTHNL CRSWRMGYRTHNLKV 1077 19.66
410 424 RAIVTDFSV TKKCRAIVTDFSVIK 1080 19.7
95 109 VNPTQAPVI PRFVDVNPTQAPVIQ 1086 19.79
94 108 FVDVNPTQA QPRFVDVNPTQAPVI 1087 19.8
763 777 TKQILRQLL GQQGPTKQILRQLLT 1089 19.83
337 351 AMNIEAPRL ARGQAMNIEAPRLPD 1094 19.9
805 819 SDKIVQAPI PGSGTSDKIVQAPIF 1095 19.91
27 41 VTQVGSEPI GDQGNVTQVGSEPIS 1096 19.93
26 40 NVTQVGSEP YGDQGNVTQVGSEPI 1098 19.96
749 763 MQLALRAPA VLPTPMQLALRAPAG 1100 19.98
750 764 QLALRAPAG LPTPMQLALRAPAGQ 1105 20.05
764 778 KQILRQLLT QQGPTKQILRQLLTG 1106 20.06
211 225 ATTYSAGIV GTRHATTYSAGIVQI 1110 20.12
230 244 NQKIETAFL DQNQKIETAFLMARR 1113 20.16
335 349 YARGQAMNI AYARGQAMNIEAPRL 1114 20.17
338 352 AMNIEAPRL RGQAMNIEAPRLPDD 1117 20.23
28 42 VTQVGSEPI DQGNVTQVGSEPISP 1119 20.25
29 43 VTQVGSEPI QGNVTQVGSEPISPE 1125 20.35
280 294 FIEFVGWLC SFIEFVGWLCKKDHT 1125 20.35
751 765 QLALRAPAG PTPMQLALRAPAGQQ 1132 20.45
30 44 VTQVGSEPI GNVTQVGSEPISPEI 1140 20.56
212 226 ATTYSAGIV TRHATTYSAGIVQIP 1146 20.64
752 766 QLALRAPAG TPMQLALRAPAGQQG 1146 20.64
417 431 FSVIKAIEE VTDFSVIKAIEEEHR 1153 20.74
269 283 IGLGTKNRV IWIGLGTKNRVSFIE 1155 20.76
136 150 FIWMCMTVR NIEEFIWMCMTVRHR 1160 20.83
209 223 HATTYSAGI DEGTRHATTYSAGIV 1164 20.89
175 189 RMGYRTHNL SWRMGYRTHNLKVNS 1169 20.96
418 432 IKAIEEEHR TDFSVIKAIEEEHRK 1173 21.01
210 224 ATTYSAGIV EGTRHATTYSAGIVQ 1176 21.05
816 830 APIFYPPVL APIFYPPVLQPIQVM 1179 21.09
339 353 AMNIEAPRL GQAMNIEAPRLPDDP 1185 21.17
145 159 RHRCQAIRK MTVRHRCQAIRKKPL 1186 21.19
663 677 WAQIGHIPY KPTWAQIGHIPYQPT 1195 21.31
450 464 VVLQRPPTQ PTVVLQRPPTQQEPG 1197 21.34
375 389 MESLKNIPQ KSGMESLKNIPQTLP 1204 21.43
374 388 MESLKNIPQ DKSGMESLKNIPQTL 1206 21.45
664 678 IGHIPYQPT PTWAQIGHIPYQPTP 1216 21.59
137 151 FIWMCMTVR IEEFIWMCMTVRHRC 1226 21.73
415 429 FSVIKAIEE AIVTDFSVIKAIEEE 1226 21.73
172 186 RMGYRTHNL SCRSWRMGYRTHNLK 1235 21.85
373 387 MESLKNIPQ EDKSGMESLKNIPQT 1239 21.91
376 390 MESLKNIPQ SGMESLKNIPQTLPY 1243 21.97
372 386 KSGMESLKN EEDKSGMESLKNIPQ 1245 21.99
171 185 WRMGYRTHN SSCRSWRMGYRTHNL 1247 22.01
127 141 LFLEQNLNI GSLFLEQNLNIEEFI 1270 22.32
135 149 FIWMCMTVR LNIEEFIWMCMTVRH 1272 22.35
86 100 VHTRQPRFV DPLDVHTRQPRFVDV 1276 22.4
511 525 VMEQRVMAT KDDEVMEQRVMATLL 1294 22.62
512 526 EQRVMATLL DDEVMEQRVMATLLP 1297 22.66
918 932 DIAVSSPSS MLGLGDIAVSSPSSS 1309 22.82
87 101 VHTRQPRFV PLDVHTRQPRFVDVN 1312 22.86
788 802 LERQAAAGW KLQAALERQAAAGWQ 1314 22.89
513 527 EQRVMATLL DEVMEQRVMATLLPP 1315 22.9
281 295 FIEFVGWLC FIEFVGWLCKKDHTH 1316 22.91
519 533 VMATLLPPV RVMATLLPPVPQQPR 1321 22.97
84 98 DVHTRQPRF GDDPLDVHTRQPRFV 1332 23.13
668 682 HIPYQPTPT QIGHIPYQPTPTGPA 1332 23.13
85 99 VHTRQPRFV DDPLDVHTRQPRFVD 1339 23.22
620 634 PMPLRPIPM APRQWPMPLRPIPMR 1340 23.23
669 683 HIPYQPTPT IGHIPYQPTPTGPAT 1355 23.41
789 803 LERQAAAGW LQAALERQAAAGWQP 1368 23.58
146 160 CQAIRKKPL TVRHRCQAIRKKPLP 1369 23.59
621 635 PMPLRPIPM PRQWPMPLRPIPMRP 1378 23.7
138 152 FIWMCMTVR EEFIWMCMTVRHRCQ 1386 23.8
790 804 LERQAAAGW QAALERQAAAGWQPS 1392 23.88
634 648 LRMQPIPFN RPLRMQPIPFNHPVG 1395 23.91
753 767 QLALRAPAG PMQLALRAPAGQQGP 1403 24.01
88 102 VHTRQPRFV LDVHTRQPRFVDVNP 1411 24.11
791 805 LERQAAAGW AALERQAAAGWQPSP 1416 24.17
917 931 MLGLGDIAV DMLGLGDIAVSSPSS 1422 24.24
913 927 MLGLGDIAV KQERDMLGLGDIAVS 1439 24.44
912 926 DMLGLGDIA AKQERDMLGLGDIAV 1442 24.48
229 243 NQKIETAFL SDQNQKIETAFLMAR 1447 24.54
213 227 ATTYSAGIV RHATTYSAGIVQIPR 1460 24.69
250 264 YTLFFDLVS AERYTLFFDLVSSGN 1474 24.87
914 928 MLGLGDIAV QERDMLGLGDIAVSS 1474 24.87
110 124 HAVYDSMLQ LVHAVYDSMLQSDLR 1486 25.01
619 633 QWPMPLRPI AAPRQWPMPLRPIPM 1487 25.02
420 434 IKAIEEEHR FSVIKAIEEEHRKKK 1492 25.08
330 344 LAYARGQAM EEIDLAYARGQAMNI 1494 25.1
495 509 GVQVHGSML SMQGVQVHGSMLDLL 1499 25.16
134 148 IEEFIWMCM NLNIEEFIWMCMTVR 1500 25.17
915 929 MLGLGDIAV ERDMLGLGDIAVSSP 1500 25.17
419 433 IKAIEEEHR DFSVIKAIEEEHRKK 1519 25.4
658 672 ITPYKPTWA EITPYKPTWAQIGHI 1519 25.4
496 510 GVQVHGSML MQGVQVHGSMLDLLE 1520 25.41
916 930 MLGLGDIAV RDMLGLGDIAVSSPS 1520 25.41
178 192 YRTHNLKVN MGYRTHNLKVNSFES 1537 25.61
328 342 IDLAYARGQ TNEEIDLAYARGQAM 1562 25.89
659 673 ITPYKPTWA ITPYKPTWAQIGHIP 1575 26.04
416 430 FSVIKAIEE IVTDFSVIKAIEEEH 1578 26.07
242 256 ARSLSAERY ARRARSLSAERYTLF 1583 26.14
228 242 NQKIETAFL ISDQNQKIETAFLMA 1628 26.66
100 114 VNPTQAPVI VNPTQAPVIQLVHAV 1635 26.74
270 284 GLGTKNRVS WIGLGTKNRVSFIEF 1657 26.99
227 241 NQKIETAFL RISDQNQKIETAFLM 1659 27.02
247 261 LSAERYTLF SLSAERYTLFFDLVS 1672 27.18
421 435 IKAIEEEHR SVIKAIEEEHRKKKA 1673 27.19
920 934 DIAVSSPSS GLGDIAVSSPSSSET 1675 27.21
248 262 YTLFFDLVS LSAERYTLFFDLVSS 1678 27.25
331 345 LAYARGQAM EIDLAYARGQAMNIE 1683 27.3
919 933 DIAVSSPSS LGLGDIAVSSPSSSE 1695 27.43
775 789 VKKGRPSLK LLTGGVKKGRPSLKL 1698 27.46
181 195 NLKVNSFES RTHNLKVNSFESGGD 1702 27.5
329 343 LAYARGQAM NEEIDLAYARGQAMN 1709 27.58
776 790 KKGRPSLKL LTGGVKKGRPSLKLQ 1717 27.67
307 321 KPWLRAHPV PKAAKPWLRAHPVAI 1737 27.89
308 322 KPWLRAHPV KAAKPWLRAHPVAIP 1739 27.92
494 508 GVQVHGSML ESMQGVQVHGSMLDL 1747 28
249 263 YTLFFDLVS SAERYTLFFDLVSSG 1756 28.1
332 346 LAYARGQAM IDLAYARGQAMNIEA 1782 28.39
921 935 DIAVSSPSS LGDIAVSSPSSSETS 1787 28.45
660 674 YKPTWAQIG TPYKPTWAQIGHIPY 1795 28.53
182 196 VNSFESGGD THNLKVNSFESGGDN 1798 28.57
309 323 KPWLRAHPV AAKPWLRAHPVAIPY 1803 28.62
176 190 RMGYRTHNL WRMGYRTHNLKVNSF 1804 28.64
179 193 NLKVNSFES GYRTHNLKVNSFESG 1818 28.78
216 230 AGIVQIPRI TTYSAGIVQIPRISD 1832 28.94
217 231 AGIVQIPRI TYSAGIVQIPRISDQ 1832 28.94
140 154 WMCMTVRHR FIWMCMTVRHRCQAI 1859 29.21
218 232 AGIVQIPRI YSAGIVQIPRISDQN 1859 29.21
243 257 ARSLSAERY RRARSLSAERYTLFF 1880 29.44
493 507 GVQVHGSML EESMQGVQVHGSMLD 1882 29.46
408 422 TKKCRAIVT KSTKKCRAIVTDFSV 1901 29.64
777 791 KKGRPSLKL TGGVKKGRPSLKLQA 1902 29.65
520 534 VMATLLPPV VMATLLPPVPQQPRA 1918 29.81
177 191 RMGYRTHNL RMGYRTHNLKVNSFE 1931 29.94
833 847 TAMAASAVT GGSPTAMAASAVTQA 1936 29.98
778 792 KKGRPSLKL GGVKKGRPSLKLQAA 1943 30.06
678 692 TMLLRQWAP PTGPATMLLRQWAPA 1945 30.08
635 649 PLRMQPIPF PLRMQPIPFNHPVGP 1954 30.18
139 153 WMCMTVRHR EFIWMCMTVRHRCQA 1985 30.48
487 501 LLHEESMQG TAVLLHEESMQGVQV 1990 30.53
832 846 TAMAASAVT QGGSPTAMAASAVTQ 2009 30.71
834 848 TAMAASAVT GSPTAMAASAVTQAP 2009 30.71
831 845 PTAMAASAV GQGGSPTAMAASAVT 2011 30.73
762 776 PTKQILRQL AGQQGPTKQILRQLL 2023 30.85
407 421 TKKCRAIVT AKSTKKCRAIVTDFS 2057 31.18
111 125 VHAVYDSML VHAVYDSMLQSDLRP 2064 31.24
215 229 AGIVQIPRI ATTYSAGIVQIPRIS 2069 31.3
485 499 LLHEESMQG QVTAVLLHEESMQGV 2089 31.49
142 156 TVRHRCQAI WMCMTVRHRCQAIRK 2103 31.65
486 500 LLHEESMQG VTAVLLHEESMQGVQ 2103 31.65
383 397 TLPYNPTVY NIPQTLPYNPTVYGR 2119 31.8
779 793 KKGRPSLKL GVKKGRPSLKLQAAL 2127 31.89
180 194 NLKVNSFES YRTHNLKVNSFESGG 2134 31.96
382 396 TLPYNPTVY KNIPQTLPYNPTVYG 2139 32.01
381 395 PQTLPYNPT LKNIPQTLPYNPTVY 2165 32.24
241 255 ARSLSAERY MARRARSLSAERYTL 2177 32.35
214 228 ATTYSAGIV HATTYSAGIVQIPRI 2183 32.41
406 420 TKKCRAIVT DAKSTKKCRAIVTDF 2204 32.59
497 511 VQVHGSMLD QGVQVHGSMLDLLEK 2226 32.79
404 418 STKKCRAIV KSDAKSTKKCRAIVT 2265 33.15
113 127 DSMLQSDLR AVYDSMLQSDLRPLG 2269 33.18
478 492 WQPLPGPQV WQPLPGPQVTAVLLH 2277 33.25
193 207 VHPVLVTAT GGDNVHPVLVTATLG 2283 33.3
194 208 VHPVLVTAT GDNVHPVLVTATLGC 2291 33.37
891 905 VVILENVGQ PVVILENVGQGQQQT 2291 33.37
294 308 IREWFRQCT THIREWFRQCTGRPK 2301 33.46
579 593 SQLSSSAPS SPTTSQLSSSAPSCA 2303 33.48
405 419 TKKCRAIVT SDAKSTKKCRAIVTD 2309 33.53
116 130 LQSDLRPLG DSMLQSDLRPLGSLF 2329 33.71
661 675 WAQIGHIPY PYKPTWAQIGHIPYQ 2330 33.72
488 502 LLHEESMQG AVLLHEESMQGVQVH 2341 33.8
786 800 LKLQAALER SLKLQAALERQAAAG 2346 33.85
195 209 VHPVLVTAT DNVHPVLVTATLGCD 2366 34.03
305 319 PKAAKPWLR GRPKAAKPWLRAHPV 2372 34.08
477 491 WQPLPGPQV PWQPLPGPQVTAVLL 2372 34.08
445 459 PESQAPTVV PESQAPTVVLQRPPT 2377 34.12
821 835 LQPIQVMGQ PPVLQPIQVMGQGGS 2378 34.13
662 676 WAQIGHIPY YKPTWAQIGHIPYQP 2384 34.18
310 324 WLRAHPVAI AKPWLRAHPVAIPYD 2394 34.26
387 401 PTVYGRPAV TLPYNPTVYGRPAVF 2395 34.27
112 126 DSMLQSDLR HAVYDSMLQSDLRPL 2405 34.35
389 403 PTVYGRPAV PYNPTVYGRPAVFDR 2452 34.75
822 836 IQVMGQGGS PVLQPIQVMGQGGSP 2455 34.77
385 399 TLPYNPTVY PQTLPYNPTVYGRPA 2459 34.8
388 402 PTVYGRPAV LPYNPTVYGRPAVFD 2459 34.8
114 128 MLQSDLRPL VYDSMLQSDLRPLGS 2461 34.82
219 233 IVQIPRISD SAGIVQIPRISDQNQ 2488 35.04
384 398 TLPYNPTVY IPQTLPYNPTVYGRP 2508 35.2
143 157 RHRCQAIRK MCMTVRHRCQAIRKK 2520 35.29
296 310 FRQCTGRPK IREWFRQCTGRPKAA 2526 35.34
885 899 ASHSPVVIL GGASHSPVVILENVG 2533 35.39
295 309 FRQCTGRPK HIREWFRQCTGRPKA 2542 35.47
89 103 VHTRQPRFV DVHTRQPRFVDVNPT 2564 35.64
748 762 TPMQLALRA QVLPTPMQLALRAPA 2564 35.64
144 158 RHRCQAIRK CMTVRHRCQAIRKKP 2571 35.69
577 591 TTSQLSSSA LTSPTTSQLSSSAPS 2601 35.93
183 197 VNSFESGGD HNLKVNSFESGGDNV 2602 35.94
580 594 SQLSSSAPS PTTSQLSSSAPSCAQ 2605 35.97
754 768 QLALRAPAG MQLALRAPAGQQGPT 2627 36.14
128 142 LFLEQNLNI SLFLEQNLNIEEFIW 2641 36.26
141 155 TVRHRCQAI IWMCMTVRHRCQAIR 2645 36.29
746 760 VLPTPMQLA PPQVLPTPMQLALRA 2656 36.37
581 595 SQLSSSAPS TTSQLSSSAPSCAQT 2657 36.37
377 391 MESLKNIPQ GMESLKNIPQTLPYN 2663 36.42
578 592 SQLSSSAPS TSPTTSQLSSSAPSC 2663 36.42
747 761 VLPTPMQLA PQVLPTPMQLALRAP 2668 36.46
311 325 WLRAHPVAI KPWLRAHPVAIPYDD 2671 36.49
378 392 MESLKNIPQ MESLKNIPQTLPYNP 2685 36.6
274 288 RVSFIEFVG GTKNRVSFIEFVGWL 2688 36.63
244 258 LSAERYTLF RARSLSAERYTLFFD 2689 36.63
484 498 VLLHEESMQ PQVTAVLLHEESMQG 2697 36.69
426 440 HRKKKAART IEEEHRKKKAARTEQ 2703 36.73
424 438 EHRKKKAAR KAIEEEHRKKKAART 2705 36.75
425 439 HRKKKAART AIEEEHRKKKAARTE 2706 36.76
327 341 IDLAYARGQ LTNEEIDLAYARGQA 2708 36.77
386 400 NPTVYGRPA QTLPYNPTVYGRPAV 2731 36.95
451 465 VVLQRPPTQ TVVLQRPPTQQEPGP 2744 37.06
828 842 VMGQGGSPT QVMGQGGSPTAMAAS 2753 37.13
427 441 HRKKKAART EEEHRKKKAARTEQP 2756 37.15
297 311 FRQCTGRPK REWFRQCTGRPKAAK 2757 37.16
390 404 PTVYGRPAV YNPTVYGRPAVFDRK 2759 37.17
115 129 MLQSDLRPL YDSMLQSDLRPLGSL 2764 37.21
340 354 AMNIEAPRL QAMNIEAPRLPDDPI 2772 37.27
99 113 VNPTQAPVI DVNPTQAPVIQLVHA 2776 37.29
129 143 LFLEQNLNI LFLEQNLNIEEFIWM 2800 37.46
780 794 KKGRPSLKL VKKGRPSLKLQAALE 2800 37.46
184 198 VNSFESGGD NLKVNSFESGGDNVH 2802 37.48
90 104 VHTRQPRFV VHTRQPRFVDVNPTQ 2823 37.64
273 287 RVSFIEFVG LGTKNRVSFIEFVGW 2829 37.68
510 524 VMEQRVMAT EKDDEVMEQRVMATL 2851 37.84
835 849 TAMAASAVT SPTAMAASAVTQAPT 2860 37.91
428 442 HRKKKAART EEHRKKKAARTEQPR 2872 37.99
290 304 HTHIREWFR KKDHTHIREWFRQCT 2947 38.54
829 843 VMGQGGSPT VMGQGGSPTAMAASA 2949 38.56
326 340 EEIDLAYAR PLTNEEIDLAYARGQ 2961 38.64
892 906 VVILENVGQ VVILENVGQGQQQTL 2978 38.77
132 146 IEEFIWMCM EQNLNIEEFIWMCMT 2984 38.81
670 684 HIPYQPTPT GHIPYQPTPTGPATM 3009 38.99
131 145 NLNIEEFIW LEQNLNIEEFIWMCM 3016 39.03
192 206 VHPVLVTAT SGGDNVHPVLVTATL 3017 39.04
492 506 MQGVQVHGS HEESMQGVQVHGSML 3019 39.05
291 305 HTHIREWFR KDHTHIREWFRQCTG 3050 39.27
409 423 RAIVTDFSV STKKCRAIVTDFSVI 3052 39.28
272 286 GLGTKNRVS GLGTKNRVSFIEFVG 3063 39.36
818 832 PVLQPIQVM IFYPPVLQPIQVMGQ 3071 39.42
333 347 YARGQAMNI DLAYARGQAMNIEAP 3073 39.43
820 834 LQPIQVMGQ YPPVLQPIQVMGQGG 3076 39.45
636 650 PIPFNHPVG LRMQPIPFNHPVGPT 3083 39.49
745 759 VLPTPMQLA PPPQVLPTPMQLALR 3129 39.79
744 758 VLPTPMQLA TPPPQVLPTPMQLAL 3139 39.85
245 259 LSAERYTLF ARSLSAERYTLFFDL 3140 39.86
31 45 VTQVGSEPI NVTQVGSEPISPEIG 3164 40.02
830 844 QGGSPTAMA MGQGGSPTAMAASAV 3168 40.04
817 831 PIFYPPVLQ PIFYPPVLQPIQVMG 3181 40.13
208 222 GTRHATTYS CDEGTRHATTYSAGI 3192 40.19
306 320 KPWLRAHPV RPKAAKPWLRAHPVA 3218 40.36
226 240 RISDQNQKI PRISDQNQKIETAFL 3223 40.4
32 46 VTQVGSEPI VTQVGSEPISPEIGP 3233 40.46
133 147 IEEFIWMCM QNLNIEEFIWMCMTV 3233 40.46
298 312 FRQCTGRPK EWFRQCTGRPKAAKP 3256 40.62
303 317 PKAAKPWLR CTGRPKAAKPWLRAH 3257 40.62
334 348 YARGQAMNI LAYARGQAMNIEAPR 3265 40.67
819 833 LQPIQVMGQ FYPPVLQPIQVMGQG 3279 40.76
38 52 ISPEIGPFE EPISPEIGPFELSAA 3286 40.8
302 316 PKAAKPWLR QCTGRPKAAKPWLRA 3296 40.86
498 512 VHGSMLDLL GVQVHGSMLDLLEKD 3297 40.87
617 631 APRQWPMPL ETAAPRQWPMPLRPI 3297 40.87
652 666 VEITPYKPT HQTPQVEITPYKPTW 3309 40.95
220 234 IVQIPRISD AGIVQIPRISDQNQK 3315 40.98
618 632 QWPMPLRPI TAAPRQWPMPLRPIP 3345 41.17
509 523 DDEVMEQRV LEKDDEVMEQRVMAT 3348 41.19
793 807 LERQAAAGW LERQAAAGWQPSPGS 3358 41.26
288 302 HTHIREWFR LCKKDHTHIREWFRQ 3367 41.32
881 895 GGASHSPVV EMPHGGASHSPVVIL 3370 41.34
651 665 QVEITPYKP PHQTPQVEITPYKPT 3428 41.71
489 503 LHEESMQGV VLLHEESMQGVQVHG 3446 41.82
191 205 DNVHPVLVT ESGGDNVHPVLVTAT 3447 41.83
39 53 IGPFELSAA PISPEIGPFELSAAS 3450 41.85
452 466 VVLQRPPTQ VVLQRPPTQQEPGPV 3453 41.86
743 757 PQVLPTPMQ PTPPPQVLPTPMQLA 3457 41.89
380 394 PQTLPYNPT SLKNIPQTLPYNPTV 3468 41.95
677 691 ATMLLRQWA TPTGPATMLLRQWAP 3479 42.01
185 199 VNSFESGGD LKVNSFESGGDNVHP 3512 42.23
882 896 GGASHSPVV MPHGGASHSPVVILE 3539 42.39
922 936 IAVSSPSSS GDIAVSSPSSSETSN 3544 42.42
341 355 AMNIEAPRL AMNIEAPRLPDDPII 3557 42.5
41 55 IGPFELSAA SPEIGPFELSAASED 3562 42.53
196 210 PVLVTATLG NVHPVLVTATLGCDE 3618 42.85
40 54 IGPFELSAA ISPEIGPFELSAASE 3624 42.88
587 601 SCAQTPWPV SSAPSCAQTPWPVVQ 3640 42.98
282 296 GWLCKKDHT IEFVGWLCKKDHTHI 3644 43
304 318 PKAAKPWLR TGRPKAAKPWLRAHP 3646 43.01
774 788 GGVKKGRPS QLLTGGVKKGRPSLK 3648 43.02
271 285 IGLGTKNRV IGLGTKNRVSFIEFV 3655 43.07
586 600 SCAQTPWPV SSSAPSCAQTPWPVV 3677 43.2
883 897 GGASHSPVV PHGGASHSPVVILEN 3713 43.41
588 602 SCAQTPWPV SAPSCAQTPWPVVQP 3719 43.44
42 56 IGPFELSAA PEIGPFELSAASEDD 3741 43.56
287 301 LCKKDHTHI WLCKKDHTHIREWFR 3754 43.65
301 315 GRPKAAKPW RQCTGRPKAAKPWLR 3764 43.71
589 603 SCAQTPWPV APSCAQTPWPVVQPS 3767 43.73
755 769 QLALRAPAG QLALRAPAGQQGPTK 3817 44.01
868 882 RAKIEAYTE PSKRAKIEAYTEPEM 3822 44.03
880 894 GGASHSPVV PEMPHGGASHSPVVI 3835 44.11
879 893 EMPHGGASH EPEMPHGGASHSPVV 3860 44.24
197 211 PVLVTATLG VHPVLVTATLGCDEG 3862 44.25
246 260 LSAERYTLF RSLSAERYTLFFDLV 3925 44.59
289 303 HTHIREWFR CKKDHTHIREWFRQC 3950 44.72
379 393 LKNIPQTLP ESLKNIPQTLPYNPT 3977 44.87
728 742 VPRQRPRGA QVPPVPRQRPRGAPT 3995 44.97
708 722 VPRQRPRGA EVPPVPRQRPRGAPT 4008 45.04
792 806 LERQAAAGW ALERQAAAGWQPSPG 4046 45.24
391 405 TVYGRPAVF NPTVYGRPAVFDRKS 4057 45.29
709 723 VPRQRPRGA VPPVPRQRPRGAPTP 4082 45.43
729 743 VPRQRPRGA VPPVPRQRPRGAPTP 4082 45.43
671 685 HIPYQPTPT HIPYQPTPTGPATML 4143 45.73
686 700 LRQWAPATM LRQWAPATMQTPPRA 4148 45.76
869 883 IEAYTEPEM SKRAKIEAYTEPEMP 4159 45.81
852 866 RRGVGPMPP TRERRGVGPMPPTDI 4208 46.06
423 437 IKAIEEEHR IKAIEEEHRKKKAAR 4301 46.55
853 867 VGPMPPTDI RERRGVGPMPPTDIP 4332 46.7
710 724 VPRQRPRGA PPVPRQRPRGAPTPT 4350 46.78
730 744 VPRQRPRGA PPVPRQRPRGAPTPT 4350 46.78
773 787 GGVKKGRPS RQLLTGGVKKGRPSL 4369 46.88
585 599 LSSSAPSCA LSSSAPSCAQTPWPV 4379 46.93
463 477 VGPLSVQAR PGPVGPLSVQARLEP 4388 46.97
469 483 ARLEPWQPL LSVQARLEPWQPLPG 4493 47.47
422 436 IKAIEEEHR VIKAIEEEHRKKKAA 4535 47.66
462 476 VGPLSVQAR EPGPVGPLSVQARLE 4542 47.7
726 740 PVPRQRPRG PPQVPPVPRQRPRGA 4577 47.86
706 720 PVPRQRPRG PPEVPPVPRQRPRGA 4605 47.99
221 235 IVQIPRISD GIVQIPRISDQNQKI 4618 48.05
854 868 VGPMPPTDI ERRGVGPMPPTDIPP 4636 48.14
855 869 VGPMPPTDI RRGVGPMPPTDIPPS 4638 48.15
1 15 MKKAWLSRA MKKAWLSRAQQADAG 4646 48.18
461 475 VGPLSVQAR QEPGPVGPLSVQARL 4651 48.2
555 569 HDQLLPAPG STEPVHDQLLPAPGP 4693 48.41
576 590 TTSQLSSSA PLTSPTTSQLSSSAP 4695 48.42
556 570 HDQLLPAPG TEPVHDQLLPAPGPD 4762 48.72
727 741 VPRQRPRGA PQVPPVPRQRPRGAP 4762 48.72
707 721 VPRQRPRGA PEVPPVPRQRPRGAP 4775 48.77
490 504 EESMQGVQV LLHEESMQGVQVHGS 4800 48.88
499 513 VHGSMLDLL VQVHGSMLDLLEKDD 4817 48.96
575 589 TSPTTSQLS QPLTSPTTSQLSSSA 4837 49.05
464 478 VGPLSVQAR GPVGPLSVQARLEPW 4914 49.39
293 307 HTHIREWFR HTHIREWFRQCTGRP 4936 49.5
557 571 HDQLLPAPG EPVHDQLLPAPGPDP 4943 49.53
470 484 LEPWQPLPG SVQARLEPWQPLPGP 4962 49.61
856 870 VGPMPPTDI RGVGPMPPTDIPPSK 4971 49.66
582 596 LSSSAPSCA TSQLSSSAPSCAQTP 4987 49.72
Legend to Table S5
The analysis of binding of the peptides to HLA DR2b was done using the Immune Epitope Data Base or IEDB 
(www. iedb.org). The default peptide length of 15 amino acids was used in the analysis but the sequence of 
the core nonamer peptide that is expected to bind to the HLA DR molecule and constitute the major portion of 
the T cell epitope is shown (column 3) for each 15 mer sequence (column 4). The starting and ending amino 
acid residue number for each nonamer in the protein sequence are shown in columns 1 and 2 respectively. The 
analysis was done using the Stabilised Matrix Method (SMM) where the peptides are ranked according to their 
predicted binding affinities or IC50 (column 5) which indicates the concentration of peptide in nM expected to 
achieve 50% saturation of the HLA DR molecule. Therefore a lower IC50 shows a higher affinity. As a guide, 
peptides with IC50 values <50 nM are considered to bind with high affinity, between 50nM to 500 nM with 
intermediate affinity and between 500nM to 5000 nM with low affinity. For each peptide, a percentile rank 
(columns 6) is generated by comparing the peptide's score against the scores of five million random 15 mers 
selected from the SWISSPROT protein database. Therefore smaller percentile rank values, typically <10, also 
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